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Hepatic cytochrome P450 (P450) mediated metabolism, which includes the metabolism of both 
endogenous and exogenous chemicals, is an important process in the maintenance of 
homeostasis and normal physiological function in humans. The expression and function of P450 
genes are controlled by multiple regulatory factors and show great inter-individual differences. 
Understating the underlying regulatory mechanisms to P450 genes is critical to evaluate the 
metabolism capability and predict drug efficacy or toxicity. Long noncoding RNAs (lncRNAs) 
are a class of recently discovered regulatory molecules in gene expression and function, which 
are highly involved in multiple physiological activities across different species. Recent studies 
also suggest that lncRNAs are involved in metabolism activities in humans. However, there is a 
significant knowledge gap in understating how lncRNAs influences the expression and function 
of P450 genes and downstream drug metabolism. The research project in this thesis mainly 
focuses on understating the roles of two transcription factor neighborhood lncRNAs, HNF1α-
antisense-1 (HNF1α-AS1) and HNF4α-antisense-1 (HNF4α-AS1), in the regulation of P450 
expression and P450 mediated drug metabolism. My results demonstrate that lncRNAs HNF1α-
AS1 and HNF4α-AS1 are able to regulate the expression of multiple P450 genes and P450 
related transcription factors, including CAR and PXR. In addition, the manipulation of these 
lncRNAs further impacted P450 mediated drug metabolism and toxicity.  Taken together, these 
studies indicate the critical regulatory roles of lncRNAs in drug metabolism through the 
regulation of hepatic P450s. A better understanding of how lncRNAs impact drug usage in 
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Chapter 1. Introduction 
 
1.1 Liver and drug metabolism 
Liver is the major organ responsible for metabolism and biotransformation, which is critical 
for the maintenance of homeostasis status in the human body. The substrates of liver metabolism 
include both endogenous compounds, for example of glucose, lipids, and steroids, and exogenous 
chemicals, such as environmental toxicants and drugs. 
It has been reported that the majority of orally delivered pharmaceutical drugs will go through 
liver mediated metabolism [1,2]. As most drug molecules are lipophilic in nature, it is difficult for 
the drugs to be excreted from the human body in their native form directly. The overall aim of 
drug metabolism is to transform the lipophilic drug compounds into a more hydrophilic form to 
facilitate the excretion of the drugs from the human body through body fluids, such as urine and 
bile.  
Generally, the hepatic metabolism of the drugs is divided into two phases, Phase I metabolism 
and Phase II metabolism. However, not all drugs will go through all these two phases to get 
excreted. Some drugs might just undergo one phase and some drugs might be excreted directly 
without being metabolized. Still, a majority of clinical used drugs go through Phase I and Phase II 
metabolism sequentially before being excreted. 
In Phase I metabolism, drugs will go through reactions including oxidation, reduction, and 
hydrolysis. The purpose of these reactions is to add certain chemical groups to the drug molecules 
and make them more water-soluble.  
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Oxidation is the most common reaction in Phase I metabolism, where a single oxygen atom is 
added onto the drug molecules. Hepatic cytochrome P450s (P450) are the major mediators of 
oxidation reactions in the liver. Examples of drugs undergoing oxidation metabolism include 
acetaminophen (APAP), codeine, and omeprazole. 
Reduction usually results in additions of hydrogen groups to drug molecules. Similar to the 
oxidation reactions, reductions can also be catalyzed by P450s and often occur under anaerobic 
conditions. An example drug undergoing reduction metabolism is warfarin, an anticoagulant drug 
that is inactivated by metabolism. 
Hydrolysis is also a Phase I reaction. However, P450s do not mediate this type of reactions. 
The activities of the drugs can be altered in many different ways after being metabolized. For 
most clinically used drugs, the metabolism leads to decreases in drug activity or causes drug 
inactivation. For some drugs, including drugs termed as prodrugs, the metabolism can generate 
active metabolites that have higher activities as compared to their parent drugs. Still, the activities 
of some drugs do not change much after being metabolized. 
Conjugation reactions are the major type of Phase II metabolism. By adding of ionized groups 
to the drug molecules, conjugation reactions significantly increase the water solubility of drugs, 
allowing drug excretion through urine and bile. Phase II metabolism reactions are mediated by a 
group of conjugating enzymes, including UDP-glucuronosyltransferases (UGTs), 
sulfotransferases (SULTs), N-acetyltransferases (NATs), and glutathione S-transferases (GSTs). 
Unlike Phase I metabolism, Phase II metabolism usually results in the inactivation of drugs or the 
active Phase I metabolites of drugs.  
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After the process of metabolism, lipophilic drug molecules generally transform into 
hydrophilic metabolites and excrete through body fluids.  
 
1.2 Cytochrome P450s enzymes  
P450 enzymes are a group of oxidase enzymes, which are able to mediate reactions including 
oxidation, sulfoxidation, aromatic hydroxylation, aliphatic hydroxylation, N-dealkylation, O-
dealkylation, and deamination [1]. P450s are involved in both exogenous detoxification and 
endogenous biosynthesis or degradation processes.  
P450 enzymes are expressed in a variety of living organisms, including humans, primates, 
rodents, plants, bacteria, and fungi. In humans, more than 155 P450 genes and pseudogenes have 
been annotated. The nomenclature system for P450s was developed by Nebert in the late 1980s. 
The name of each individual P450 gene or enzyme consists of three parts, one family number, one 
subfamily letter, and one identifying number. Human P450 members start with CYP1A1 and end 
with CYP51P3 [3].  
P450s are distributed in multiple organs and sites in the human body, including liver, kidney, 
intestine, brain, and blood cells. At all these different sites, hepatic P450s contributes to the 
majority of the metabolic function. Furthermore, the abundance of P450 members in the liver is 
not equally distributed. In adult human livers, CYP3A4 is the most abundant P450 isoform, 
followed by CYP2E1, 2C9, 1A2, 2A6, and 2C8 (Figure 1.1) [4]. Based on protein content, these 
six P450 enzymes contribute to almost 80% of all hepatic P450 enzymes. However, the abundance 
of P450 isoforms does not fully represent their metabolism capability regarding currently used 
prescription drugs. Zanger and Schwab summarized the metabolic functions of P450s in a total 
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number of 248 clinical used drugs [5]. According to their results, CYP3A4 has the highest number 







Figure 1. 1 The abundances of P450 isoforms in human liver. 
The abundance of hepatic P450 isoforms were measured and compared by mean protein value 











Figure 1. 2. Fraction of P450 isoforms in metabolizing clinically used drugs. 
A total number of 248 clinical used drugs with known P450 mediated metabolism were 
summarized and analyzed. Each metabolic pathway was counted only once for the major 
contributing P450 isoform. (Data retrieved from [5]) 
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1.3 Variabilities in cytochrome P450s 
One major characteristic of P450s is the existence of significant variabilities. One study 
comparing the Japanese and Caucasians hepatic microsomal P450s found that the contents for 
several P450 isoforms were highly variable. Specifically, more than 50-fold variations were found 
in CYP2A6, 2B6, and 2D6, a 20-fold variation in 1A2, a 12-fold variation in 2E1, and 5-fold 
variation in 3A4 [6]. In another study focusing on the variation in CYP3A content found a 64-fold 
variation in 20 donor livers, with a protein abundance range from 4 to 262 pmol/mg [7]. In addition 
to the expression of P450 enzymes, variances can also be found in the P450 mediated drug 
metabolic rate. A 31-fold variation was observed in the rate of testosterone 6β-hydroxylation 
mediated by CYP3A4 [8]. A 100-fold variation was observed in the rate of dextromethorphan O-
demethylation mediated by CYP2D6 [9]. In addition, a 40-fold variation was observed in the rate 
of S-mephenytoin 4’-hydroxylation mediated by CYP2C9 [9]. 
In addition to the interindividual variations, the function and expression of P450s can also be 
different within the same individual. It has been reported that age and health conditions also affect 
the metabolic function of an individual, which are partially contributed by P450 dysregulation.  
 
1.4 Regulatory factors in P450 expression and function 
For drugs that undergoing P450 mediated metabolism, the variations in P450s will significantly 
influence their therapeutic efficacy and toxicity in patients. Due to this, identifying the regulatory 
factors that cause changes in P450 expression and functions is critical for a better understanding 
of the mechanisms of P450 regulation and P450-associated guidance of clinical drug use. 
8 
 
Several well-established regulatory factors have been identified controlling the expression and 
function of P450s, including genetic factors, epigenetic factors, and physiological factors. In this 
section, these well-established regulatory factors will be discussed. 
 
1.4.1 Genetic polymorphisms  
As part of the pharmacogenetic study, the heritable changes on the genetic sequence of drug-
metabolizing P450 genes and their effects on certain P450 isoforms and clinical relevance have 
been studied for over sixty years [10]. Single nucleotide polymorphisms (SNPs) and copy number 
variants (CNVs) are the two major polymorphisms identified in P450s genes, which cause either 
enhanced or repressed enzymatic activities. It has been reported that most loss-of-function 
polymorphisms in P450s genes happen at the level of mRNA splicing or expression, rather than 
protein expression or structure [11]. The gain-of-function polymorphisms have multiple 
mechanisms. The first type of gain-of-function polymorphisms is due to increased number of 
functional gene copies (CNVs), this applies to CYP2D6, and CYP2A6 [12]. The second gain-of-
function polymorphisms is increased substrate turnover due to variants in the promoter or amino 
acid level, CYP2B6, 2C8, and 2C19 have been reported to be affected by this mechanism.  
The type, frequency, functional effect, and clinical relevance of currently identified P450 
polymorphisms have been summarized in several publications, which will not be discussed in 
detail here [5,13-15]. 
The impacts of certain genetic polymorphisms on each P450 gene can vary significantly. Some 
may lead to phenotype changes while others may not. Based on the phenotypes associated with 
certain polymorphisms, the population could be divided into several groups: poor metabolizer, 
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intermediate metabolizer, extensive metabolizer, rapid metabolizer, and ultra-rapid metabolizer. 
Among all these groups, extensive metabolizers refer to people with “normal” metabolic capability, 
which also account for the majority of the population. When taking drugs, extensive metabolizers 
will experience both therapeutic benefits and adverse effects. Intermediate metabolizers refer to 
people with reduced P450 activity but still can metabolize a drug. Poor metabolizers have little to 
no capability to metabolize usually due to polymorphisms causing loss-of-function in P450s. 
Compared to extensive metabolizers, intermediate or poor metabolizers should be dosed with less 
amount of drugs due to their limited metabolism capability. Intermediate or poor metabolizers may 
experience more sever adverse effects because of slower clearance of a toxic drug. They may also 
experience less therapeutic effect, when taking prodrugs, which need to be activated by 
metabolism. Rapid and ultra-rapid metabolizers usually carry gain-of-function polymorphisms to 
certain P450s, which give them a much greater capability to metabolize drugs. Dose adjustment 
should also be considered when giving drugs to rapid and ultra-rapid metabolizers. For drugs 
working in their parent form, higher doses will be needed to ensure the therapeutic effects, while 
prodrugs may require lower doses to avoid excessive toxicity.  
In clinical practice, based on the knowledge of how genetic polymorphisms affect P450-
mediated drug metabolism, the U.S. Food and Drug Administration has added special instructions 
on several drugs to ensure the safety when being prescribed to patients carrying certain P450s 
alleles. However, genetic polymorphisms were reported to account for less than 30% of the 
interindividual variances in P450 expression and function, indicating the existence and importance 





1.4.2 Epigenetic regulations 
Epigenetics refers to the regulation of gene expression or phenotype, which does not cause 
alterations in the DNA sequences. Comparing to genetic polymorphisms, epigenetic modifications 
are mostly reversible and may be influenced by many factors such as age or disease. Mechanisms 
involved in epigenetic regulation are DNA methylation, histone modifications, and noncoding 
RNAs. There is increasing evidence showing that epigenetic alterations are highly involved in 
P450 regulation and have great clinical implications [17].   
DNA methylation refers to the process of adding methyl groups to the CpG islands with the 
help of DNA methyltransferases. Hyper-methylated DNA sequences are usually associated with 
gene repression, while hypo-methylated DNA sequences are associated with gene activation.  
DNA methylation has been shown to regulate the expression of multiple P450 genes, including 
CYP1A2, 2D6, and 2E1 [18]. Furthermore, DNA methylation has been shown to affect drug-
induced liver injury by regulating certain P450 enzymes [19,20]. 
Histone modifications are another common epigenetic mechanism in P450 regulation. 
Depending on the types of added chemical groups, histone modifications can be further divided 
into histone acetylation, which is mediated by histone acetyltransferases and deacetylases, and 
histone methylation, which is mediated by histone methyltransferases and demethylases. Histone 
modifications mainly affect the accessibility and transcriptional activity of the modified genes by 
altering chromatin structures. Acetylation of histone tails usually leads to gene activation. 
Knockdown of a histone deacetylase was reported to induce the expression of CPY2B10 in mouse 
livers and CYP2B6 in HepG2 cells [21]. The effects of histone methylation on gene expression 
are variable, depending on the modification sites and the number of added methyl groups. One 
study showed that the transcriptional activity of CYP2C9 gene was regulated by the methylation 
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status of histone 3 lysine 27 (H3K27) tail, which affected the binding of HNF4α to the promoter 
region of CYP2C9 gene [22]. H3K4 tri-methylation and H3K27 tri-methylation were also reported 
to be important for rifampicin induced expression of CYP3A4 [23].  
Recent studies also illuminated the impacts of noncoding RNAs (ncRNAs) on drug metabolism 
and P450 expression. MicroRNAs (miRNAs) are small ncRNAs that have been shown to involve 
in gene regulation through binding to target mRNAs. Several miRNAs have been identified to 
regulate the expression of P450s. The regulation of P450s by miRNAs can work either directly or 
indirectly. Examples of miRNAs that directly regulate P450s are miR-27b, which regulates 
CYP1B1 and 3A4, and miR-378, which regulates CYP2E1 [24,25]. For indirect regulation, 
miRNAs target P450 regulatory proteins, such as transcription factors, and influence P450 
expression. Examples of miRNAs include miR-27b, which regulates vitamin D receptor and 
peroxisome proliferator-activated receptor, and miR-613, which regulates liver X receptor [25,26]. 
Even though the field of P450 regulation by epigenetic mechanisms is still relatively new, there 
are numerous examples demonstrating an important impacts of DNA methylation, histone 
modifications, and ncRNAs in P450 regulation and clinical drug use. 
1.4.3 Liver enriched transcription factors 
Transcription factors are a class of proteins that control the transcription activity of target genes 
through direct binding. Several liver-enriched transcription factors have been well-characterized 
for their functions in the regulation of P450s [27]. Generally, P450 regulatory transcription factors 
can be divided into two types: 1) ones that control the basal expression of P450s, and 2) ones that 
control the induced expression of P450s. Hepatocyte nuclear factor 1α (HNF1α)  and HNF4α are 
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well-characterized type 1 transcription factors, while pregnane X receptor (PXR) and constitutive 





Figure 1. 3. Transcription factors in P450 regulation. 
(A) Diagram of general transcription factor function. 




HNF1α is a homeodomain-containing transcription factor, which is expressed in several organs 
including the liver, kidney, intestine, stomach, and pancreas. HNF1α has been reported to regulate 
the transcription of several liver-specific genes involving in liver development, lipid metabolism, 
and liver damage [28]. By combining gene studies and electrophoretic mobility shift studies, the 
potential binding site of HNF1α has been identified in several P450 genes, including CYP2E1, 
7A1, and 1A2 [29-31]. Using HNF1α deficient mice as an experimental model, Cheung et al. found 
remarkable alterations of basal expression of several hepatic P450s. Specifically, the expression 
of Cyp1a2, 2c29, 2e1, and 3a11 were reduced, while the expression of Cyp2a5, 2b10 and 2d9 were 
elevated [32]. These results pointed out the critical roles of HNF1α in the regulation of P450s, 
which might further impact drug metabolism and endogenous metabolism. 
HNF4α is another transcription factor that is widely expressed in the human liver, kidney, 
intestine, and pancreas. Previous studies have shown the implication of HNF4α in several 
functions of the liver, including fatty acid metabolism, glucose metabolism, lipoprotein synthesis, 
and liver differentiation [33-35]. HNF4α is able to bind to several motifs, including DR1 and HPF-
1 motifs. By using in vitro transfection assays in cultured cells, DR1 and HPF-1 motifs have been 
found to be important for the activation of several P450 genes by HNF4α, including rabbit CYP2C1, 
2C2, 2C3, human CYP2C9 and 2D6, rat CYP3A, and mouse CYP2D9 and CYP2A4 [36,37]. 
Knockdown of HNF4α in human hepatocytes using siRNA resulted in decreased basal mRNA 
levels of CYP2A6, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4, as well as PXR and CAR, indicating that 
HNF4α plays a dominant role in the regulation of P450s and P450 related transcription factors in 
human hepatocytes [38]. The majority of studies on HNF4α functions in P450 gene expression 
were performed in vitro. Yet, in vivo studies are still needed given the fact that multiple regulatory 
factors together contribute to the regulation of P450 expression in the liver. 
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PXR and CAR are reported to regulate the drug-induced level of P450s in the liver. Upon 
activation, both of them can form heterodimers with retinoid X receptor and bind to the response 
element sequences on target P450 genes. Binding of the heterodimer to P450 genes leads to 
transcription activation and up-regulation of P450 expression. Certain chemicals can serve as 
ligands of PXR or CAR, and induce P450 expression, including clinically used drugs. Only certain 
P450 isoforms can be induced by CAR and PXR. For example, members of the CYP2B, 2C, and 
3A subfamilies can have both PXR and CAR dependent induction, while members of the CYP1A 
subfamily can only be induced by CAR [39]. 
In addition to P450 regulation, transcription factors also regulate each other. PXR or CAR was 
previously reported to show HNF4α dependent expression, and knockdown HNF4α decreased 
mRNA levels of PXR and CAR, indicating the existence of a regulatory network in P450 and P450 




1.5 Non-coding genes and long non-coding RNAs (lncRNAs) in the genome 
The advancement of next-generation sequencing techniques leads to a more detailed and 
comprehensive investigation towards the genomes. It has been reported that the percentage of 
protein coding genes in the genomes decreases with the increases in the complexity of an organism 
(Figure 1.4) [42]. While the vast majority of the human genomes are transcribed into RNAs, around 
98% of the generated transcripts do not have protein-coding functions and are regarded as ncRNAs 
[43,44]. The genes coding for ncRNAs were once regarded as “junk” in the genomes. However, 
recent studies have revealed biological significance with diverse functions in these ncRNA 
transcripts. By definition, ncRNAs are transcripts that do not have protein coding capacity. 
However, most ncRNAs can perform their functions directly as RNA molecules, including 
structural, catalytic, and regulatory functions. Based on their functions, ncRNAs can be broadly 
divided into two classes, the housekeeping ncRNAs and regulatory ncRNAs (Figure 1.5). 
Examples of the housekeeping ncRNAs include the transfer RNAs (tRNAs), ribosomal RNAs 
(rRNAs), small nuclear RNAs (snRNAs), and small nucleolar RNAs (snoRNAs). The roles of 
these constitutively expressed housekeeping ncRNAs are involved in maintaining the normal 
cellular behaviors and their functions have been well defined [45]. Regulatory ncRNAs are the 
other type of ncRNAs widely existing across different species. Based on the length of the RNA 
transcripts, regulatory ncRNAs can be further divided into short ncRNAs (less than 200 nt in length) 
and long ncRNAs (lncRNAs) (more than 200 nt in length). Examples for short ncRNAs include 
miRNAs and small interfering RNAs (siRNAs), whose functions are reviewed elsewhere and will 
not be further discussed here [46,47].  
The biosynthesis of lncRNAs is reported to be similar to messenger RNAs (mRNAs), which 
are mediated by the RNA polymerase II. LncRNAs also have some of the distinctive features in 
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the processes of biosynthesis, including polyadenylation, alternative splicing, and RNA cleavage, 
which ultimately lead to isoforms of lncRNAs [48,49]. So far, more than 100,000 lncRNAs have 
been annotated and reported in several databases in the human genome [50,51]. However, in 
contrast to the achievements in identifying and mapping lncRNAs, the functional studies of 







Figure 1. 4. Noncoding genes in the genomes.  
The percentage of protein-coding sequences (orange portions) in several eukaryotic and bacterial 













The functions of lncRNAs are still questioned by several skepticisms.  The major debate of 
lncRNA function comes from the lack of strong sequence conservation of lncRNAs. During the 
evolutionary selection, sequences or motifs with specific functions get selected and kept in 
organisms. In this case, the level of sequence conservation has been used as an indicator of 
functional significance to newly identified genes. RNA transcripts of coding genes, the mRNAs, 
and especially the open reading frames of mRNAs, show a high level of conservation across 
species [52]. This sequence conservation helps to prevent frameshift mutations and maintain the 
normal function of coding genes. In comparison to mRNAs, lncRNAs showed only a moderate to 
low level of sequence conservation, which supports the idea to consider lncRNAs as transcriptional 
“noise” [53]. However, the idea of using sequence conservation to evaluate the functional 
significance of lncRNAs was later challenged by several points. Firstly, a low sequence 
conservation does not mean low function conservation. In fact, the lncRNAs might only need to 
be conserved in a short region to keep their functions conserved. One example is the lncRNA Xist, 
where it remained its function of X chromosome silencing in all eutherian females with a low 
sequence conservation level [54,55]. Secondly, the promoter regions of lncRNAs have been 
reported to show high conservation levels, which indicates that the transcription activity of 
lncRNAs is highly conserved, regardless of the sequences of lncRNAs themselves [56]. Moreover, 
the low conservation level might indicate higher evolutionary freedom in lncRNAs [57].  In 
addition, the low abundance of lncRNAs in the genomes is another criticism in lncRNA functions. 
The high-throughput sequencing techniques used for the detection of lncRNAs were able to detect 
transcripts with very low abundance in the cells [58,59]. Whether these lncRNAs with low 
abundance are functionally significant remains untested. The best way to address this question is 
functional validation to each annotated lncRNAs.  
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In contrast to these criticisms, several other features of lncRNAs also supported the idea that 
lncRNAs are critical regulatory molecules in the genomes: 1) expression of lncRNAs changes 
through development [60,61], 2) lncRNAs show tissue-specific expression [62,63], and 3) 
lncRNAs are dysregulated in disease conditions [64,65]. 
 
1.6 Classification of lncRNAs 
LncRNAs can be further classified based on their locations and orientations relative to coding 
genes (Figure 1.6) [66]. Intergenic lncRNAs (lincRNAs) are lncRNAs that are located between 
two coding genes. Intronic lncRNAs are lncRNAs that are positioned within the intronic region of 
a coding gene. Sense lncRNAs are lncRNAs that are transcribed from the same strain of a coding 
gene with sequence overlaps, while antisense lncRNAs are lncRNAs that are transcribed from the 
opposite strain of a coding gene with sequence overlaps. Bidirectional lncRNAs are lncRNAs that 
are transcribed from the opposite strain of a coding gene without sequence overlaps. However, this 
classification is not comprehensive or complete since the discovery of new lncRNAs is still 
ongoing. A more detailed classification of lncRNA subtypes or categories needs to be developed 












1.7 LncRNAs in gene regulation: functions and mechanisms 
The “central dogma of molecular biology” describes the flow of genetic information, where 
the genetic information coded by DNAs is transcribed into mRNAs and mRNAs are further 
translated into proteins. LncRNAs have been reported to involve in nearly every step of gene 
regulation (Figure 1.7).  
In pre-transcriptional regulation, lncRNAs can turn the target gene on or off by affecting 
chromatin structures through epigenetic modifications [67]. LncRNAs regulate histone codes in 
two ways: 1) by directly interacting with chromatin-modifying complexes, and 2) by regulating 
histone modification enzymes. LncRNA COLDAIR was reported to regulate the formation of 
H3K27 histone markers by recruiting polycomb repressive complex 2 (PRC2), one histone 
modification complex, to certain chromatin locations [68]. In another example, lncRNA 
lncPRESS1 was reported to mediate histone acetylation by directly binding to a histone 
deacetylase, SIRT6, and to cause inhibition of deacetylation on SIRT6 target genes [69]. 
LncRNAs are also involved in transcription regulation, which mainly occurs in the nucleus. 
LncRNAs impact the process of transcription in multiple ways: 1) to directly bind with DNA 
sequences and enhance or repress gene transcription, and 2) to interact with transcription related 
proteins (transcription factors) and activate or inhibit downstream target gene transcription [70,71]. 
For example, lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has 
been proven to interact with transcription factor specificity protein 1 in the activation of 
transforming growth factor-β pathways in several cancers [72].  
In the post-transcriptional process, lncRNAs are also highly involved. LncRNAs can affect the 
processes of mRNAs and alter several features of mRNAs, such as splicing and stability [73]. 
23 
 
LncRNAs regulate splicing of mRNAs mainly through interacting with splicing factors, which are 
critical in the determination of splicing sites. LncRNA MALAT1 was reported to interact with 
serine/arginine-rich splicing factor 1 and facilitate the loading of splicing factors to nuclear 
speckles. Further, knockdown of MALAT1 led to changes in splicing products of transcripts 
[74,75]. LncRNA OCC-1 was reported to regulate the stability of Hu antigen R (HuR) targeted 
mRNAs. HuR is an important stabilizing factor for a large number of mRNAs. By interacting with 
both HuR and ubiquitin E3 ligase β-TrCP1, OOC-1 led to degradation of HuR by ubiquitination, 
and thus destabilized HuR target mRNAs and downregulated them [76]. LncRNAs are also able 
to interact with miRNAs to regulate their target mRNAs [77]. By interacting with miRNAs, 
lncRNAs affect the stability of mRNAs, which are targeted by miRNAs. 
LncRNAs, by acting as translational modulators, have been reported to regulate the translation 
process in many ways. LncRNAs can modulate translational efficiency by recruiting translational 
regulating proteins to the site of translation. LncRNA-p21 was reported to repress the translation 
of β-catenin. By binding to β-catenin mRNAs, lncRNA-p21 enhanced the interaction between 
mRNAs and translational repressors, including RCK and fragile X mental retardation protein, 












Figure 1. 7. LncRNAs in the central dogma of molecular biology. 
LncRNAs have been found to involve nearly every level of gene expression. 1) In pre-
transcription, lncRNAs regulate gene expression by modifying histone markers or chromatin 
structures. 2) In post-transcription, lncRNAs regulate several features of mRNAs including RNA 
splicing or stability. 3) In translation, lncRNAs affect the efficiency of translation by recruiting 




The mechanisms of how lncRNAs regulate gene expression are complex and have not been 
fully understood yet. Comparing to the identified amount of lncRNAs, there are far fewer lncRNAs 
that have been functionally defined and assigned with explicit roles.  Nevertheless, these lncRNAs 
have shown their significance and importance in the regulation of gene expression [66,79]. Current 
insights into the lncRNAs suggest that lncRNAs can interact with different biological molecules, 
including RNAs [80,81], DNAs [80,82,83], and proteins [84,85] (Figure 1.8). The interaction with 
DNAs and formation of lncRNA-DNA duplexes or triplexes are the basis of lncRNA in gene 
regulation at the pre-transcriptional level. Examples of lncRNAs interacting with DNAs include 
ANRASSF1 and ANRIL [86,87]. LncRNAs interacting with RNAs usually associate with gene 
regulation at the post-transcriptional level, which modulates mRNA expression and functions. 
Examples of lncRNAs, which are able to interact with RNA, include BACE1-AS1 and PTENpg1 
[88-90]. LncRNAs interacting with proteins can perform diverse functions based on the protein 
functions and are involved in all levels of gene regulation. LncRNA Xist, APOA1-AS, and 














By interacting with other molecules, lncRNAs can perform their regulatory functions through 
four defined molecular mechanisms: decoy, guide, scaffold, and signal (Figure 1.9) [94]. 
LncRNAs function as decoys, which can preclude the interaction between molecules, such as 
DNA-protein interaction. Examples for this type of lncRNAs are Gas5 and PANDA [95,96]. 
LncRNAs functioning through guide and scaffold mechanisms share similar features. By binding 
with multiple molecules and concentrating them in certain sub-cellular areas, the lncRNAs can 
increase the interaction between these recruited molecules, including protein-protein interaction, 
protein-DNA interaction, and protein-RNA interaction. One of the well-studied scaffold lncRNA 
examples is HOTAIR, which can bind with two histone modification complexes, PRC2 and LSD1, 
and involves in gene regulation by histone tail modification [97]. Signal lncRNAs are defined by 
their function to activate or to repress genes or their ability to change the chromatin conformation. 
Enhancer lncRNAs are reported to have this signal function in gene regulation, with lncRNA 
HOTTIP as an example. HOTTIP was reported to directly interact with WDR5, a key component 
protein in histone modification, inducing the formation of chromosome looping and enforcing gene 
activation by maintaining histone H3K4me3 modification [98]. However, this archetype of 
classification is oversimplified sometimes as one lncRNA may function through multiple 
mechanisms. One example is the lncRNA Xist, which can regulate its target genes through both 













LncRNAs can act in both cis- and trans- manners, in terms of their functional modes (Figure 
1.10) [101,102]. LncRNAs acting as cis-regulators are mainly involved in the expression and 
function of their neighborhood coding genes, which are also likely to show expression correlation 
with coding genes. Examples for cis-acting lncRNAs include lncRNA VIM-AS1 and CARMEN 
[103,104].  On the other hand, trans-regulatory lncRNAs are involved in the regulation of distal 
genes from their transcription sites, where lncRNA Firr is an example [105]. However, with the 
progression in understanding lncRNA function, lncRNAs with both cis- and trans- regulatory 







Figure 1. 10. Schematic diagram of two modes in gene regulation by lncRNAs. 
(A) LncRNAs functioning in a cis-regulation manner are more likely to regulate nearby coding 
genes.  





1.8 Neighborhood antisense lncRNA  
An antisense transcript refers to a transcript generated from the opposite transcription from the 
opposite strand to a protein-coding or sense strand [108]. The existence of antisense transcription 
is very common across different transcriptomes and these antisense transcripts are usually co-
transcribed with their sense transcripts [109]. It has been demonstrated that more than 60% of the 
sense transcripts have antisense partners [108,110]. LncRNAs have been identified to be one 
common type of antisense transcripts of coding genes and involve in the regulation of function and 
expression of their neighborhood coding genes. 
There are several locations near a coding gene where antisense lncRNAs are likely to exist 
(Figure 1.11). However, it is still not clear how different locations affect the function of lncRNAs. 
Recent studies have found that these neighborhood lncRNAs might affect their nearby coding 
genes in multiple ways, including regulation of the coding genes or involvement in the functional 










Figure 1. 11. Locations of antisense neighborhood lncRNAs.  
Depending on the relative location towards the coding gene, neighborhood lncRNAs are 
categorized into several types: 1) Nearby to head, the 5’ end of the lncRNA is close to the 5’ end 
of the coding gene; 2) Head to head, the 5’ end of both genes are aligned together; 3) 
Overlapping, the antisense lncRNA overlaps with the sense coding gene; 4) Tail to tail, the 3’ 
end of both genes are aligned together; and 5) Nearby to tail, the 3’ end of the lncRNA is close to 




1.9 LncRNAs and transcription factors 
Along with the advancements in the discovery of lncRNAs, there is an increasing amount of 
studies trying to identify lncRNAs that have special relationships with coding genes. These 
relationships include but not limit to correlations in expression, spatial localization, and function 
[111-113].  
There is increasing evidence showing that lncRNAs, including transcription factor 
neighborhood antisense lncRNAs, are involved in the expression or functions of transcription 
factors in gene regulation [114]. In this section, lncRNAs interacting with transcription factors are 
summarized (Table 1.1). 
LncSox4 is a lncRNA highly expressed in hepatocellular carcinoma (HCC) tissues and 
epithelial ovarian cancer [115,116]. Chen and his colleagues found that the expression levels of 
LncSox4 were correlated with the outcomes of HCC treatment, where patients with higher 
LncSox4 expression usually had poorer outcomes.  LncSox4 was found to be required for the self-
renewal of the tumor-initiating cells in HCC in a loss-of-function cell model. This effect of 
LncSox4 was found to be related to its ability to interact with transcription factor signal transducer 
and activator of transcription 3 (STAT3), a transcription factor that is previously reported to have 
critical roles in cancer development and cell steaminess [117,118]. The binding of  LncSox4 to 
STAT3 resulted in the recruitment of STAT3 to the promoter region of the SOX4 gene and 
transcription activation [115].  
Lnc-DC is another lncRNA found to directly bind with transcription factor. Lnc-DC was found 
to be exclusively expressed in conventional dendritic cells of the hematopoietic system [119].  
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Table 1. 1. Examples of lncRNAs interacting with transcription factors. 
  
LncRNA Related TFs Functions Reference 
LncSox4 STAT3 Initiate self-renewal of tumor-initiating cells 
in HCC. 
Promote cell proliferation and inhibit 
apoptosis in epithelial ovarian cancer. 
[115] [116] 
Lnc-DC STAT3 Mediate differentiation, development, and 
function of dendritic cells. 
[119] 
GM10863 SOX10 Mediate synapse function through regulation 
of Sox10 levels. 
[120] 
GATA3-AS1 GATA3 Involve in differentiation and function of T 
helper 2 cells through GATA3, IL5, and 
IL13 regulation. 
[121] 
GABPB1-AS1 GABPB1 Regulate cellular antioxidant capacity and 
cell viability in HepG2 cells. 
[122] 





Using both knockdown and overexpressed methods, Wang et al. found that lnc-DC was vital for 
the differentiation process of dendritic cells. Further, they identified that lnc-DC was able to 
directly bind with STAT3 and promote the phosphorylation of STAT3 by inhibition of the binding 
of tyrosine phosphatase, SHP1, to phosphorylated STAT3. This mechanism of lnc-DC promots 
the activation of STAT3 and downstream STAT3 dependent pathways in dendritic cell 
differentiation, development, and function. 
LncRNA GM10863 was identified in a search of lncRNA:mRNA pairs (mRNAs located 
within 200 kb of the lncRNA gene body) using the UCSC genome browser performed by 
Raveendra et al. [120]. In this project, GM10863 was identified to localize in the neighborhood 
region of SOX10, which is a coding gene playing critical roles in the development and function of 
neuro. The expression of GM10863 was found to correlate with the expression of SOX10 mRNA 
in mouse primary hippocampal neurons. In addition, knockdown of GM10863 reduced the levels 
of SOX10 mRNA and protein, indicating that GM10863 and SOX10 might work as a lncRNA: 
transcription factor pair in terms of function [120]. 
GATA3-AS1 is a divergent lncRNA sharing a promoter region with transcription factor gene 
GATA3, a master regulator in T helper 2 cell functions. In one study performed by Gibbons et al., 
GATA3-AS1 was found to control the expression of GATA3 as well as two interleukin genes, IL5 
and IL13. Specifically, depletion of GATA3-AS1 resulted in a reduction in GATA3, IL5, and IL13 
mRNA and protein levels, along with decreased T helper 2 cell polarization. This regulatory 
function of GATA3-AS1 was accomplished through the interaction with histone-modifying 
enzymes and the alteration of histone codes to its own gene locus, which is the shared promoter 
region of GATA3 [121].  
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GABPB1 is a transcription factor known to regulate the transcription of various genes related 
to antioxidation process, including PRDX5 [124]. LncRNA GABPB1-AS1 is an antisense RNA 
of GABPB1, which was previously reported to response to chemical-induced cellular stress [125]. 
A recent study showed that GABPB1-AS1 was able to affect the functions of GABPB1 by 
modulating the translation process of GABPB1 in HepG2 cells, an in vitro model for HCC. The 
up-regulation of GABPB1-AS1 inhibited the translation of GABPB1, which further reduced the 
expression of peroxidase genes, including PRDX5, and accumulation of reactive oxygen species 
and lipid peroxidation in the cells [122].  
Yin Yang 1 (YY1) is an ubiquitously expressed transcription factor involved in the regulation 
of cell proliferation and differentiation [126].  In muscle cells or myoblasts, YY1 regulates genes 
involved in cell proliferation and differentiation by interacting with histone methyltransferase 
complex and alterating of histone markers on target genes [127]. Linc-YY1 is a divergently 
transcribed lncRNA located upstream of the mouse YY1-coding gene. The employment of linc-
YY1 loss- and gain-of-function assays in a mouse myoblast cell line showed that linc-YY1 was 
important in the myogenic differentiation and muscle regeneration processes, and modulation of 
linc-YY1 also affected YY1 target genes. This function of linc-YY1 was accomplished through 
interacting with YY1 directly and eviction of YY1/Polycomb repressive complex, a complex 
mediating histone methylation, from promoter regions of target genes [123]. 
 
1.10  LncRNAs in liver functions 
Up to today, a number of lncRNAs have been found to impact the liver functions in many 
aspects, both physiologically and pathologically [128]. As the major metabolic organ in the human 
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body, the liver mediates the metabolism or detoxification of both endogenous and exogenous 
materials every day. Liver dysfunction due to diseases will greatly impact the wellbeing of the 
human body and life quality. 
Previous studies mainly focus on the function of coding genes, including enzymes and 
transporters, in the metabolic functions of the liver. Recent studies showed that lncRNAs were 
also able to impact the development or metabolic activities of the liver. In this section, several 
example lncRNAs known to affect liver functions are summarized and discussed.  
 
1.10.1 LncRNAs in the liver development 
The functions of the liver are not invariable during different stages of humans, nor does the 
metabolic capability of the liver. The maturation of the liver is a process of the buildup of liver 
functions during human development, which relies on the alteration of gene expressions.  
Factors regulating the development or maturation of the liver might have direct effects on the 
metabolic capability of the liver. Recent studies find that lncRNAs also have specific expression 
patterns during different stages of liver development, which is similar to coding genes [129]. 
However, little is known about how lncRNAs are regulated during liver development or maturation 
and few lncRNAs have been identified to directly involve in this process. 
Using RNA sequencing techniques, one recent study observed dynamic transcriptional pattern 
changes of lncRNAs during the postnatal development of mouse liver [129]. More than one 
thousand hepatic lncRNAs showed differential expression levels during postnatal liver maturation. 
Furthermore, three major oncogenic expression patterns of lncRNA during liver development were 
identified, indicating that lncRNAs are involved in liver development. Another study examined 
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lncRNA expression patterns in mouse embryonic liver and adult liver and showed similar results, 
where the expression of lncRNAs followed specific patterns during liver development [130].  
 
1.10.2 LncRNAs in the endogenous metabolism  
The liver plays a critical role in the maintenance of metabolic homeostasis in humans [131]. 
This function relays on the abilities of the liver to synthesize, transform, store, and distribute 
molecules including lipid and glucose. Several hepatic lncRNAs have been identified function as 
regulatory factors of lipid or glucose levels through interference with liver functions.  
LncLSTR is a livre enriched lncRNA, whose expression level alters along with changes in 
energy levels and metabolic states. Knockdown of lncLSTR led to decreased plasma triglyceride 
level in mice due to a higher triglyceride clearance rate. Mechanistically, lncLSTR upregulated 
expression of CYP8B1 by interacting with TDP43 and disinhibiting the transcription of CYP8B1. 
The increased level of CYP8B1 further impacted bile acid composition and activated FXR and 
ApoC2 expression, which was involved in triglyceride clearance [132]. 
LncRNA lncARSR was reported to be reduced in non-alcoholic fatty liver disease (NAFLD) 
patients and a mouse model with NAFLD, a common type of human chronic liver disease 
characterized by the existence of hepatic steatosis (lipid accumulation) in patients without 
excessive alcohol consumption or fatty liver. Hepatic lipid accumulation was enhanced by 
overexpression of lncARSR while ameliorated by lncARSR knockdown, indicating that lncARSR 
involved in lipid metabolism. A mechanistic study showed that lncARSR was able to regulate the 
hepatic lipogenesis process via regulating SREBP-1c, a master regulator in lipogenesis [133]. 
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Lnc-HC was identified to be upregulated in the high-fat diet fed rat livers. Expression of lnc-
HC was showed to negatively regulate cholesterol metabolism by regulating CYP7A1 and ABCA1, 
which were important in bile acid synthesis and cholesterol efflux. Lnc-HC firstly bound with 
partner molecular hnRNPA2B1. Then the lnc-HC/hnRNPA2B1 complex directly bound to 
CYP7A1 and ABCA1 mRNAs and repressed their expression [134]. 
LncRNA SRA was reported to have a potential role in the adipogenesis process by regulating 
PPARγ pathway and P38/JNK phosphorylation in adipocytes [135]. A recent study showed that 
SRA was able to negatively regulate the expression of adipose triglyceride lipase (ATGL), a major 
hepatic triacylglycerol hydrolase in mouse liver. Forced expression SRA in hepatocytes also led 
to inhibition of ATGL expression along with the decreased activity of β-oxidation of free fatty 
acids. In this way, SRA might promote the progression of hepatic steatosis by regulation of liver 
metabolic activities [136]. 
LncRNA HULC is first identified as a cancer-related lncRNA, which is overexpressed in HCC 
[137]. A later study found that HULC was able to regulate one miRNA miR-9, through alteration 
in the methylation status of miR-9 promoter region. This HULC mediated miR-9 downregulation 
further impacted the expression and functions of downstream miR-9 target genes, which were 
involved in lipogenesis, and resulted in the accumulation of triglycerides and cholesterol [138]. 
APOA1-AS1 is an antisense lncRNA of APOA1 gene. APOA1, which is primarily synthesized 
in the liver, is a major component of high-density lipoprotein in plasma. APOAl is also important 
for reverse cholesterol transport and efflux of cholesterol from tissues [139]. The level of high-
density lipoprotein is closely related to the susceptibility of several cardiovascular diseases in 
humans. APOA1-AS1 was found to negatively regulate the expression of the APOA1 both in vitro 
and in vivo through affecting the histone markers of the APOA1 gene [92].  
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Glucose is another important molecule in energy metabolism whose level also needs to be 
tightly controlled. The liver mediates glucose level by a balanced system consisted of glucose 
uptake, glucose storage, glycogenolysis, and gluconeogenesis. Recent studies found that several 
lncRNAs were involved in the hepatic glucose metabolism by regulating coding genes in this 
process. 
Expression of lncRNA lncSHGL was found to be reduced in obese mouse livers, and its human 
homolog lncRNA B4GALT1-AS1 was also found to be reduced in human livers with steatosis. 
By overexpressing and knockdown of lncSHGL in mice, Wang et al. found that lncSHGL was 
able to affect the process of gluconeogenesis [140]. Specifically, lncSHGL overexpression was 
associated with suppressed gluconeogenesis in high-fat diet mice, whereas lncSHGL knockdown 
was associated with promoted hyperglycemia in normal mice. Mechanistically, lncSHGL 
enhanced the translation of calmodulin mRNA, a regulatory factor in gluconeogenic and lipogenic 
pathways, by recruitment of heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) [140].  
Hepatic glucokinase is an important regulatory factor mediating the transformation of the liver 
from a glucose-consuming to a gluconeogenic organ under fasting conditions. LncRNA lncLGR 
was found to downregulate the expression of glucokinase through transcription suppression, and 
further impacted reduces hepatic glycogen content in vivo [141]. 
Expression of lncRNA Gm10768 was reported to be positively correlated with the glucose 
production in mouse primary hepatocytes, indicating a potential role of Gm10768 in hepatic 
gluconeogenesis. Overexpression of Gm10768 resulted in the activation of hepatic 
gluconeogenesis in a cell autonomous manner and depletion of Gm10768 suppressed hepatic 
glucose production. Mechanistically, Gm10768 sequestrated miRNA miR-214 from its target 
genes and dis-inhibit transcription factor 4, a positive regulator of hepatic gluconeogenesis [142]. 
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Transcription factor MAFG is identified as a regulatory factor in hepatic energy metabolism 
[143]. One recent study found that MAFG performed this function through a set of obesity-
associated hepatic lncRNAs. LncIRS2 is one of these identified lncRNAs which was controlled by 
MAFG and repressed under obese conditions. Depletion of LincIRS2 altered glucose metabolism 
shown as elevated blood glucose level, insulin resistance, and aberrant glucose output [144]. These 
results defined a novel coding gene-lncRNA axis in controlling hepatic glucose metabolism. 
 
1.10.3 LncRNAs in liver diseases 
LncRNAs have also been found to have critical functions in several kinds of liver diseases, 
including fatty liver disease, liver fibrosis, and liver cancer [145-149]. Different roles of lncRNAs 
in these diseases have been identified. 
LncRNAs have the potential to work as biomarkers for disease diagnosis. LncRNAs were 
found to be differentially expressed in health liver comparing to the diseased liver, including 
NASH, NAFLD, liver fibrosis, and HCC. LncRNA APTR was identified to have the functions of 
cell cycle and proliferation [150]. Expression of APRT was found to be higher in fibrotic livers of 
mice and humans, where knockdown of APRT attenuated liver fibrosis in CCl4-treated mouse 
livers [151]. Serum levels of APTR were also found to be higher in individuals with cirrhotic livers 
of undisclosed etiology comparing to healthy livers, or in patients with decompensated cirrhosis 
comparing to compensated cirrhosis, indicating that APTR may serve as biomarkers for liver 
fibrosis. The plasma levels of lncRNA XLOC_014172 and LOC149086 were found to correlate 
with tumorigenesis and metastasis in HCC, indicating that these two lncRNAs may serve as 
biomarkers for HCC diagnosis or metastasis markers [152].  
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Recent studies also found that lncRNAs have potential roles in regulating drug treatment 
outcomes by modulation of cellular functions, including apoptosis, DNA repair, or drug processing, 
including drug metabolism and transport [153]. Tsang et al. found that knockdown of lncRNA 
H19 suppressed the mRNA expression of MDR1 and P-gp, which are well-known drug efflux 
transporters. This inhibition of drug efflux transporters also increased the sensitivity of HCC cells 
to doxorubicin treatment [154]. LncRNA TUG1 was reported to have similar effects regarding the 
regulation of drug efflux transporter genes and drug efficacy [155].   
In summary, there is increasing evidence showing that lncRNAs are highly involved in liver 
physiology and functions. However, one major function of the liver is to metabolize exogenous 
chemicals, such as drugs. There is still a huge knowledge gap regarding whether lncRNAs are 
involved in liver mediated drug metabolism. Studies are urgently needed to address this question 




 Table 1. 2 LncRNAs involved in metabolic function of liver. 
Liver function LncRNA LncRNA function Reference 
Lipid metabolism  lncLSTR Enhance triglyceride 
clearance and decrease 
circulating triglyceride level. 
[132] 
lncARSR Enhance hepatic lipogenesis. [133] 
lnc-HC Repress cholesterol 
metabolism. 
[134] 
SRA Repress genes involved in 
triacylglycerol hydrolase and 
activity of β-oxidation of 
free fatty acids. 
[136] 
HULC Promote lipogenesis and 
stimulate the accumulation 
of intracellular triglycerides 
and cholesterol 
[138] 








Glucose and lipid 
metabolism 






LncLGR Reduce hepatic glycogen 
storage by transcriptional 
repression of glucokinase 
expression. 
[141] 
Gm10768 Promote gluconeogenesis in 
mouse liver. 
[142] 
LincIRS2 Knockdown of LincIRS2 
caused elevated glucose 




1.11 LncRNA HNF1α-AS1 and HNF4α-AS1 
 
1.11.1 Genomic locations and structures of HNF1α-AS1 and HNF4α-AS1 
HNF1α-AS1, a neighbor antisense lncRNA gene of the human HNF1α gene, is located at 
human Chromosome 12 with a length of 39.04 kb, containing 2 exons and 1 intron. The coding 
gene HNF1α and noncoding gene HNF1α-AS1 formed a typical transcription factor-lncRNA pair 
(Figure 1.12A). The coding potential of HNF1α-AS1 was analyzed by the Coding Potential 
Calculator (http://cpc2.cbi.pku.edu.cn) [156]. The testing results suggest that HNF1α-AS1 is a 
non-coding transcript (Figure 1.13A). 
HNF4α-AS1, a neighbor antisense lncRNA gene of the human HNF4α gene, is located at 
human Chromosome 20 with a length of 17.96 kb, containing 4 exons and 3 introns. The HNF4α 
and HNF4α-AS1 genes also form a typical pair of coding and neighborhood antisense non-coding 
genes (Figure 1.12B). Coding potential analysis also confirms the noncoding nature of HNF4α-


















Figure 1. 13. Coding potential analysis for HNF1α-AS1 and HNF4α-AS1. 
Data is retrieved from Coding Potential Calculator (http://cpc2.cbi.pku.edu.cn), accessed on 
3/16/2020. 
The result for HNF1α-AS1 analysis is available at : 
http://cpc2.cbi.pku.edu.cn/run_cpc2_result.php?userid=200317082945537 








As mentioned above, HNF1α and HNF4α are well-studied transcription factors, controlling the 
expression of numerous liver-specific genes. A specific tissue distribution pattern of HNF1α 
mRNA was retrieved from the RNA-Seq Expression Data GTEx in 53 tissues from 570 donors 
and showed relatively higher expression levels in the stomach, small intestine, colon, liver, 
pancreas, and kidney, the major organs in the gastrointestinal (GI) tract (Figure 1.14A) [157]. A 
similar pattern in the GI tract organs was also found for HNF1α-AS1 (Figure 1.14A), indicating 
that HNF1α-AS1 is expressed in the organs where HNF1α is expressed. These results may suggest 
that HNF1α-AS1 is possibly involved in the regulatory function of HNF1α in the GI tract organs. 
Similar tissue distribution patterns are also found between HNF4α and HNF4α-AS1 in the GI tract 
organs (Figure 1.14B). These similarities in tissue distribution might suggest functional 














Figure 1. 14. Tissue expression patterns of HNF1α, HNF1α-AS1, HNF4α, and HNF4α-AS1 
(A) Tissue expression patterns of HNF1α and HNF1α-AS1. (B) Tissue expression patterns of 
HNF4α and HNF4α-AS1. Data are retrieved from GTEx database 




In addition to the chromatin locations, the structures of lncRNAs are also important for their 
function and mechanism of action.  RNA molecules have been shown to adopt higher-order tertiary 
interactions [158]. Even though the relationships between lncRNA structure and functions are still 
not fully understood yet, identification of structural domains, which mediate the interactions 
between lncRNAs and other molecules, is critical for the characterization of lncRNA functions. 
The secondary structures of HNF1α-AS1 was predicated using RNAfold program 
(http://rna.tbi.univie.ac.at//cgi-bin/RNAWebSuite/RNAfold.cgi). The secondary structure of 
HNF4α-AS1 was not predicated as the sequence length of HNF1α-AS1 exceeds the upper limit of 
lncRNA FASTA input for the program.  
As shown in Figure 1.15, HNF1α-AS1 is able to form a stable secondary structure based on 
minimum free energy calculation. Several domains are also observed on the secondary structure 
of HNF1α-AS1. However, it is still not very clear what molecules interact with these domains and 









Figure 1. 15. Predication of HNF1α-AS1 secondary structure by RNAfold. 
(A) Minimum free energy structure of HNF1α-AS1.  
(B) Mountain plot representation of the MFE structure, the thermodynamic ensemble of RNA 
structures, and the centroid structure. The positional entropy for each position is presented at the 
bottom.   
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1.11.2 Current understanding in HNF1α-AS1 and HNF4α-AS1 functions 
Several functions of HNF1α-AS1 and HNF4α-AS1 have been reported in publications. In this 
section, the identified functions of HNF1α-AS1 and HNF4α-AS1 will be summarized and 
discussed. 
Currently, a number of studies have shown that HNF1α-AS1 is actively involved in different 
stages of cancer, including tumorigenesis, progression, and treatment. Significantly differentially 
expressed HNF1α-AS1 has been found in several types of cancer tissues comparing to normal 
tissues. However, the regulation patterns are different. Specifically, HNF1α-AS1 was upregulated 
in esophageal, lung, bladder and colon cancers, and downregulated in gastric and pancreatic 
cancers [159-164]. These controversial results indicated that HNF1α-AS1 might have tissue-
specific functions. Most studies showed that the high expression levels of HNF1α-AS1 were 
associated with a poor prognosis, a higher risk of metastasis, and a lower overall survival rate in 
cancers [160,163,165-167].  
HNF1α-AS1 plays a contradictory role in the development of cancer. Based on the cancer type, 
HNF1α-AS1 was reported to function as either oncogene or tumor-suppressing gene. Zhang et al. 
reported that HNF1α-AS1 promoted carcinogenesis in colorectal cancer by activating Wnt/β-
catenin signaling pathway, indicating that HNF1α-AS1 might be used as a prognostic biomarker 
in colorectal cancer [168]. In HCC, HNF1α-AS1was reported in one study to work as a tumor 
repressor by decreasing tumor growth and metastasis [169]. However, two other studies focusing 
on the roles of HNF1α-AS1 in HCC defined HNF1α-AS1 as an oncogene based on its function to 
promote cell proliferation and hepatocarcinogenesis [167,170]. 
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For the progression of cancer, HNF1α-AS1 mainly regulates tumor growth and metastasis. 
Knockdown of HNF1α-AS1 was reported to reduce cell proliferation rate in several in vitro cancer 
cell lines, which might further affect tumor growth [166,171,172].  Metastasis is another major 
activity during cancer progression. HNF1α-AS1 was also reported to involve in cancer metastasis 
by regulating cell migration, invasion, colony formation, and epithelial-mesenchymal transition 
(EMT), and knockdown of HNF1α-AS1 resulted in decreased cell movement or invasion, which 
might further impact the metastasis of tumor [163,166,171-174]. 
Drug resistance is the major cause of treatment failure in cancer treatment. Several mechanisms 
have been identified to contribute to the development of drug resistance in cancer cells, including 
promoted cell survival and altered drug metabolism [175]. The expression of HNF1α-AS1 was 
reported to affect the sensitivity of cancer cells to anti-cancer drugs. Cisplatin is a widely used 
chemotherapeutic drug for the treatment of cervical cancer. In one study performed by Luo et al., 
knockdown of  HNF1α-AS1 in cisplatin-resistant HeLa re-sensitized the cells to cisplatin treatment, 
indicating that HNF1α-AS1 was involved in the regulation of drug resistance in cancer cells [176]. 
In summary, based on the findings in the current published articles, HNF1α-AS1 is an 
important regulatory molecule in cancer biology. However, controversy still exists in the roles of 
HNF1α-AS1 in cancers, and future studies are needed to clarify the functions of HNF1α-AS1. 
In terms of HNF4α-AS1, the functional study is still very limited. HNF4α-AS1 was found to 
be differentially expressed in HCC compared with adjacent cirrhotic tissues using RNA 
sequencing techniques, indicating that HNF4α-AS1 may function as a biomarker for the 
development of HCC in patients with cirrhosis [177]. Using co-expression and functional 
annotation enrichment analyses across several tissues and cell types, Haberman and his colleagues 
reported that HNF4α-AS1 was significantly down-regulated in patients with Crohn's disease, 
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where the expression of HNF4α-AS1 also showed association with an epithelial metabolic 
signature, indicating that HNF4α-AS1 might be a novel inflammatory signal or therapeutic target 
for Crohn's disease [178]. 
 
1.11.3 Regulatory factors HNF1α-AS1 and HNF4α-AS1 
The knowledge regarding how the expression of HNF1α-AS1 and HNF4α-AS1 get regulated 
in cells is still very limited. According to literatures, these lncRNAs are can be regulated by their 
neighborhood genes coded proteins, which are HNF1α and HNF4α. 
One study identified HNF1α-AS1 as an HNF1α regulated lncRNA by comparing lncRNA 
expressions in HNF1α overexpressed and knockdown Huh-7 cells. This result was further 
confirmed by the existence of HNF1α response element in the promoter region of HNF1α-AS1 and 
the positive expression correlation between HNF1α and HNF1α-AS1 in several HCC cell lines 
and human HCC samples [169]. Early growth response protein 1, a transcription factor involved 
in cancer development, was also reported to regulate expression of HNF1α-AS1 by directly 
binding to the promoter region of HNF1α-AS1 and activating its transcription [179].  
Guo and Lu reported that the expression of HNF4α-AS1 was strongly activated by P1-HNF4α, 
which is predominantly produced in adult liver, but not P2-HNF4α, which is prevalent in fetal 
liver, pancreas, and liver/colon cancer, indicating that HNF4α-AS1 might be a biomarker for P1-





1.11.4 Mechanisms of HNF1α-AS1 and HNF4α-AS1 in gene regulation 
Identifying the interacting molecules to lncRNAs is the key to understand the mechanisms 
involved in lncRNA function. According to current literatures, HNF1α-AS1 functions by 
interaction with miRNAs and proteins. However, what are the interacting molecules to HNF4α-
AS1 is still largely unknown. 
HNF1α-AS1 has been reported to interact with miRNAs in cancer cells to regulate cell 
characteristics including proliferation, movement, and apoptosis. By acting as a miRNA sponge, 
HNF1α-AS1 was able to dis-inhibit the expression of genes by sponging miRNAs away from their 
target genes. The miRNAs interacting with HNF1α-AS1 are summarized in Table 1.3.    
HNF1α-AS1 was also reported to interact with functional proteins involved in cancer. Ding et 
al. found that HNF1α-AS1 was able to directly bind to the C-terminal of Src homology region 2 
domain-containing phosphatase 1 (SHP-1) with a high binding affinity [169]. SHP-1 is a non-
receptor protein tyrosine phosphatase, which predominantly expressed in haematopoietic cells,  
and function as a negative regulator of inflammation and tumor suppressor. Inhibition of SHP-1 
activity resulted in promoted tumor growth and metastasis [181]. SHP-1 was also reported to be 
regulated by HNF1α in rat hepatocytes [182]. By interacting with SHP-1, HNF1α-AS1 increased 
the phosphatase activity of SHP-1 and performed its tumor-suppressing function. 
Furthermore, HNF1α-AS1 was reported to interact with enzymes or complexes involved in 
epigenetic modification. Using RNA immunoprecipitation, HNF1α-AS1 was found to be able to 
interact with DNA methyltransferase (cytosine-5) 1 (DNMT1) in A549 cell lines, and polycomb 
repressive complex 2 member enhancer of zeste 2 (EZH2) complex in SMCC-7721 and Huh7 cell 
lines [170,171]. DNMT1 and EZH2 are critical proteins involved in DNA methylation and histone 
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methylation, respectively. These findings suggested that HNF1α-AS1 might regulate target genes 





















miRNA Cancer type Reference 
miR-30b-5p HCC，bladder cancer [162,167] 
miR-34a colon cancer [163] 
miR-17-5p NSCLC [172] 
miR-661 Gastric cancer [179] 
miR-149-5p NSCLC [183] 
miR-34b Cervical cancer [176] 
miR-124 Colorectal cancer [173] 
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1.12 Aim of the project 
Despite the development in understanding lncRNAs functions, there is a lack of knowledge 
about how lncRNAs may impact hepatic P450s and P450 mediated drug metabolism process. The 
expression and function of P450 are critical to ensure drug efficacy and safety for clinical usages. 
However, great interindividual variability exists in P450s and the mechanisms of P450 regulation 
are still not fully understood yet. Identifying new regulatory factors and understating their 
mechanisms are keys to promote the knowledge in P450 and drug metabolism, which also benefit 
clinical drug use and safety.  
The current research project is significantly relevant to the treatment of human diseases with 
drugs. The goal of drug therapy is to achieve therapeutic efficacy and to avoid toxicity. To reach 
these goals, it is critical to understand how drug-metabolizing enzymes are regulated. HNF1α and 
HNF4α are two key transcription factors in the regulation of expression of certain drug-
metabolizing enzymes, including some cytochrome P450s. However, how these transcription 
factors regulate target P450s and other P450-regulating transcription factors are still largely 
unknown. 
The central hypothesis of the current research is HNF1α-AS1 and HNF4α-AS1, which are two 
transcription factor neighborhood lncRNAs, are involved in the regulation of P450 genes, P450-
regulating transcription factors, and P450-mediated drug metabolism. In order to test this 
hypothesis, the functional analysis of lncRNAs was performed by the generation of loss-of-
function models with gene-editing techniques. Multiple assays are also used to test the effects of 
lncRNA knockdown on gene and protein expression, cell viability, and cytotoxicity.  
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The results generated in this research project will provide knowledge needed to unravel and 




Chapter 2. A Transcriptional Regulatory Network 
Containing Nuclear Receptors and lncRNAs Controls 
Basal and Drug-Induced Expression of Cytochrome 
P450s in HepaRG Cells 
 
2.1 Introduction 
Enzymes belonging to the cytochrome P450 (P450) superfamily are responsible for primarily 
metabolizing of 70-80% prescription drugs [184]. Inter-individual variability in P450-mediated 
drug metabolism exists in the general population, which leads to variability in therapeutic efficacy 
and adverse drug reactions [5]. In addition to genetic polymorphisms in the P450 genes, the 
variability in P450 expression is a major cause of inter-individual difference in P450-mediated 
drug metabolism [185]. Therefore, it is critical to understand how P450 expression is regulated, 
particularly at transcriptional level.  
Transcription of P450 expression is regulated at two different conditions: normal physical 
condition (basal level) and challenged conditions when exposing to drugs or xenobiotics (induced 
level). It has been accepted that the basal expression of P450s is regulated by two key transcription 
factors: HNF1α and HNF4α.  HNF1α and HNF4α have been proven as key transcriptional 
regulators in the control of expression of a wide range of hepatic genes at normal physical 
conditions across different species, including various P450s [31,32,186-192]. HNF1α and HNF4α 
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mainly control transcription of their target genes by direct DNA binding to the promoter regions 
[193,194]. The existence of binding site for liver-enriched transcription factors in numerous liver 
specific genes further supported the important role of HNF1α and HNF4α in hepatic gene 
regulation [195,196].  
The induced levels of P450s are controlled by two “xenobiotic sensor” nuclear receptors: CAR 
and PXR. Activation of these nuclear receptors by drugs can result in induced expression of target 
P450 genes [197-199]. CAR mainly regulates induction of CYP2B subfamily and can be activated 
by phenobarbital (PB) [200]. PXR mainly regulates induction of CYP3A subfamily and can be 
activated by rifampicin (RIF) [201].  
Studies have shown the complexity of network interaction between nuclear receptors in the 
regulation of P450s. HNF1α deficiency in mice has showed altered expression in several nuclear 
receptors [32]. HNF4α has been shown to regulate PXR and CAR and effected induction of 
downstream P450s [202]. Further, HNF4α was reported to positively regulate HNF1α [203]. 
However, no research studies the network among PXR, CAR, HNF1α, and HNF4α in a single 
system.  
Long non-coding RNAs (lncRNAs) refer to RNA transcripts longer than 200 nucleotides that 
have no protein coding function [204,205]. Recent studies have showed that lncRNAs are involved 
in regulation of neighborhood genes [114,206-209]. The involvement of lncRNAs has been shown 
in multiple physiological processes, including metabolism and diseases [210,211]. The gene 
coding for lncRNA HNF1α -AS1 is located on human chromosome 12, next to the HNF1α gene. 
HNF1α -AS1 was first identified to regulate cell proliferation and migration of human esophageal 
adenocarcinoma (EAC) cells [159]. Following studies showed that HNF1α -AS1 also involved in 
tumorigenesis and metastatic progression of several other cancer types [161,168,170,212].  The 
63 
 
gene coding for lncRNA HNF4α -AS1 is located on human chromosome 20, which overlaps with 
HNF4α gene. Based on previous data on lncRNAs, we hypothesized that HNF1α -AS1 and HNF4α 
-AS1 are involved in a transcription network with other transcription factors in the regulation of 
expression of P450s.  
HepaRG cells were selected as the experimental model due to a previous study showing that 
HepaRG cells express comparable levels of P450s and transcription factors as human primary 
hepatocytes [213].  Furthermore, HepaRG cells also respond to different P450 inducers and 
inhibitors [214-216].  
In order to study the control of expression of P450s by a regulatory network containing nuclear 
receptors and lncRNAs, we used small interference RNA (siRNA) and small hairpin RNA (shRNA) 
to perform gene knockdown in HepaRG cells and investigated the effects on expression of selected 
nuclear receptors, lncRNAs, and P450s. 
 
2.2 Materials and Methods 
2.2.1 Chemicals and Reagents 
HepaRG cells were kindly provided by Biopredic International (Rennes, France). ADD710 
growth additives and ADD720 differentiation additives were purchased from Biopredic 
International. William’s E Media (WEM), collagen I coated T-25 flasks, collagen I coated 12-well 
plates, Glutamax™ Supplement, Opti-MEM medium were obtained from Thermo Fisher 
Scientific (Carlsbad, CA). siRNAs, including a negative control (Catalog number: 4390843), 
GAPDH (Catalog number: 4390849), CAR (siRNA ID: s19369), PXR (siRNA ID: 138582), 
HNF4α (siRNA ID: s6698), HNF1α (siRNA ID: s13868), HNF1α -AS1 (siRNA ID: n265372), 
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and HNF4α -AS1 (siRNA ID: n356309), Lipofectamine™ RNAiMAX transfection reagent, and 
Lipofectamine™ stem transfection reagent were provided by Thermo Fisher Scientific (Carlsbad, 
CA). shRNA negative control and shRNAs targeting HNF1Α -AS1 were obtained from 
GeneCopoeia (Rockville, MD). Phenobarbital sodium salt and rifampicin were purchased from 
Sigma-Aldrich (St. Louis, MO). Antibodies against GAPDH, CAR, and PXR were obtained from 
Abcam (Cambridge, MA). Anti- HNF1α antibody and TRIzol™ reagent were purchased from 
Invitrogen (Carlsbad, CA). Anti- HNF4α antibody and anti-rabbit IgG antibody were obtained 
from Cell Signaling Technology (Danvers, MA).  
 
2.2.2 Cell Culture 
HepaRG cells were cultured following a protocol from Biopredic International. Briefly, a 
three-step protocol was used to generate fully differentiated HepaRG cells. Cells were first thawed 
and cultured in HepaRG growth medium (William’s E Media supplied with Glutamax™ and 
ADD710 growth additives) for two weeks in order to reach full confluence. Cells were next 
cultured in a 1:1 mixture of HepaRG growth medium and a HepaRG differentiation medium 
(William’s E Media supplied with Glutamax™ and ADD720 growth additives) for one week. In 
the last step, cells were cultured in HepaRG differentiation medium for another week to reach a 
full differentiation status. During the whole process, cells were incubated at 37°C and 5% CO2 
with the medium changed every 3 days. Fully differentiated cells were either used directly in T-25 






2.2.3 siRNA Transfection 
For siRNA transfection, fully differentiated HepaRG cells were transfected with different 
siRNAs (negative control, HNF1α, HNF1α -AS1, HNF4α, HNF4α -AS1, CAR, and PXR) using 
the Lipofectamine™ RNAiMAX Transfection Reagent according to manufacturer’s protocol. 
Sixteen hours after transfection, the siRNA-containing medium was replaced with a normal 
HepaRG differentiation medium. RNAs and proteins harvested at 48 hours after siRNA 
transfection were used for knockdown efficiency and analysis of basal expression of P450s.  
 
2.2.4 shRNA Transfection 
For shRNA transfection, undifferentiated HepaRG cells were stably transfected with four 
different shRNAs targeting HNF1α -AS1 or negative control shRNA using the Lipofectamine™ 
stem transfection reagent. Positive transfected cells were selected by puromycin treatment (3 
μg/ml). After antibiotic selection, cells were cultured to full differentiated status and harvested for 
RNA isolation. 
 
2.2.5 Drug Treatment 
For drug treatment, siRNA transfected HepaRG cells were treated with 1 mM phenobarbital 
sodium salt, 10 µM rifampicin, or PBS (vehicle) for 24 hours. After drug treatment, RNAs were 







2.2.6 RNA Isolation and Quantitative Real-Time PCR (RT-PCR) 
Total RNAs were isolated from HepaRG cells using a TRIzol™ reagent according to the 
manufacturer’s protocol. RNA concentration was measured by a Nano Drop spectrophotometer 
(Nano Drop Technologies, Wilmington, DE) at 260 nm and RNA integrity was evaluated using an 
Agilent 2200 Tape Station (Agilent Technologies, Santa Clara, CA). One µg of total RNAs was 
subjected to cDNA synthesis using an iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, 
Hercules, CA). Real-time PCR was performed using a CFX96™ Real-Time System (Bio-Rad 
Laboratories, Hercules, CA) with the primer sequences shown in Table 2.1. Expression of GAPDH, 
HNF1α, HNF4α, CAR, PXR, AHR, HNF1α -AS1, CYP1A2, 2B6, 2C8, 2C9, 2C19, 2E1, and 3A4 
were measured using an iTaq™ Universal SYBR® Green Supermix (Bio-Rad Laboratories, 
Hercules, CA) and expression of HNF4α -AS1 was measured using a TaqMan™ Gene expression 
assay (Life Technologies, Carlsbad, CA). Relative mRNA expression levels were determined by 




Table 2. 1 List of primers used for real time PCR. 
 
SYBR Primers (Integrated DNA Technologies, Coralville, IA) 
 
TaqMan™ primer (Life Technologies, Carlsbad, CA) 
Gene Assay ID 
GAPDH Hs99999905_m1 
HNF4α-AS1 Hs01378672_m1 
Gene Primer Sequence 
GAPDH Forward 5′-GGGAGCCAAAAGGGTCAT-3′ 
Reverse 5′-GAGTCCTTCCACGATACCAA-3′ 
CAR Forward 5’-TGATCAGCTGCAAGAGGAGA-3’ 
Reverse 5’-AGGCCTAGCAACTTCGCATA-3’ 
PXR Forward 5’-CCAGGACATACACCCCTTTG-3’ 
Reverse 5’-CTACCTGTGATGCCGAACAA-3’ 
Ahr Forward 5’-ACATCACCTACGCCAGTCGC-3’ 
Reverse 5’-TCTATGCCGCTTGGAAGGAT-3’ 
HNF1α Forward 5'‐CCCTGGGTCCTACGTTCA‐3' 
Reverse 5'‐GGGTCACATGGCTCTGCA-3’  






CYP1A2 Forward 5’-CCAACGTCATTGGTGCCATG-3’ 
Reverse 5’-GTGATGTCCCGGACACTGTTC-3’ 
CYP2B6 Forward 5’-AGACGCCTTCAATCCTGACC-3’ 
Reverse 5’-CCTTCACCAAGACAAATCCGC-3’ 
CYP2C8 Forward 5’-GGACTTTATGGATTGCTTCCTG-3’ 
Reverse 5’-CCATATCTCAGAGTGGTGCTTG-3’ 
CYP2C9 Forward 5’-GACATGAACAACCCTCAGGACTTT-3’ 
Reverse 5’-TGCTTGTCGTCTCTGTCCCA-3’ 
CYP2C19 Forward 5’-GAACACCAAGAATCGATGGACA-3’ 
Reverse 5’-TCAGCAGGAGAAGGAGAGCATA-3’ 
CYP2E1 Forward 5’-AATGGACCTACCTGGAAGGAC-3’ 
Reverse 5’-CCTCTGGATCCGGCTCTCATT-3’ 




2.2.7 Protein Sample Preparation and Quantification by Western Blotting 
Cell lysates were prepared from HeapRG cells cultured in collagen I coated T-25 flasks with 
RIPA buffer (supplied with protease inhibitor cocktail). Protein concentrations were determined 
using a Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA). Eighty µg of proteins were loaded and 
run on a polyacrylamide gel using a Mini-PROTEAN Tetra System (Bio-Rad Laboratories, 
Hercules, CA). Proteins were then transferred onto a PVDF membrane and blocked in 5% BSA 
for 1 hour. After blocking, the membrane was incubated with an antibody diluted in 2.5% BSA 
(anti-GAPDH 1:4000, anti-HNF1α 1:1000, anti-HNF4α 1:1000, anti-CAR 1:500, and anti-PXR 
1:1000) overnight. Then the membrane was incubated in an anti-rabbit IgG antibody (1:2000) 
diluted in 2.5% BSA.  Protein bands were visualized using a ChemiDoc MP Imaging System (Bio-
Rad, Hercules, CA). Semi quantification of proteins was calculated as the relative expression 
against GAPDH using an ImageJ program (National Institutes of Health, USA). 
 
2.2.8 Statistical Analysis 
The data are shown as mean ± SD (standard deviation).  The significance of differences 
between means was determined using a two-tailed unpaired Student’s t test. Statistical analyses 
were performed using Prism7, version 7.01 from GraphPad Software, Inc. (La Jolla, CA, USA). 




2.3.1 Impact on Regulation of P450s by Knockdown of CAR 
To evaluate the role of CAR in affecting expression of the selected transcription factors, 
lncRNAs, and P450s, HepaRG cells were transfected with a siRNA targeting CAR and mRNA 
expression of the selected genes were evaluated by RT-PCR. Knockdown efficiency of CAR after 
siRNA transfection into HepaRG cells was confirmed with a decrease of 76% in mRNA level 
determined by RT-PCR and a decrease of 65% in protein level detected by Western blot (Figure 
2.1A). Next, the mRNA expression of other examined transcription factors involved in P450 
regulation was analyzed. As shown in Figure 2.1B, mRNA expression of HNF4α, HNF1α, PXR, 
and AHR was not affected by CAR knockdown. Expression of lncRNAs, HNF4α -AS1 and 
HNF1α -AS1, were also not affected by CAR knockdown (Figure 2.1C). Among the selected drug-
metabolizing P450s, basal mRNA expression of CYP2B6, 2E1, and 3A4, which were known CAR 
regulated P450s, showed statistically significant decreases (Figure 2.1D). In contrast, mRNA 
expression of CYP1A2 was increased in HeapRG cells with CAR knockdown (Figure 2.1D). To 
measure the effect of CAR knockdown to drug-induced P450 expression, HepaRG cells were 
treated with either PB or RIF after CAR knockdown by siRNA. As shown in Figure 2.1E, the 
induction levels were lower for CYP2B6 (3.4 fold change to 1.5 fold change in the induction level 
after CAR knockdown by PB treatment), 2C19 (2.9 fold change to 1.6 fold change in the induction 
level after CAR knockdown by PB treatment), and 3A4 (9.3 fold change to 4.3 fold change in the 








Figure 2. 1.  Changes of gene expression by CAR knockdown. 
(A) Suppression of CAR expression in both mRNA (left) and protein (right) levels by siRNA 
transfection into HepaRG cells. (B) Expression of the selected transcription factors after CAR 
knockdown. (C) Expression of HNF4α -AS1 or HNF1α -AS1 after CAR knockdown. (D) 
Expression of the selected P450s at basal levels after CAR knockdown. (E) Expression of the 
selected P450s at induced levels with treatment of either phenobarbital (PB) or rifampicin (RIF) 
after CAR knockdown. The sample size for each group is n = 3. Data are shown as mean ± SD. *p 






2.3.2 Impact on Regulation of P450s by Knockdown of PXR 
The role of PXR in expression of the selected transcription factors, lncRNAs, and P450s was 
studied with a similar experimental design as CAR. Knockdown efficiency of PXR was evaluated 
by RT-PCR and Western blot after siRNA transfection into HepaRG cells. As shown in Figure 
2.2A, expression of PXR mRNA and protein was decreased to approximately 43% and 40% of the 
control, respectively. Expression of HNF4α, HNF1α, and AHR was not affected by PXR 
knockdown, while expression of CAR decreased after PXR knockdown (Figure 2.2B). For 
lncRNAs, there were slight decreases in expression of HNF4α -AS1 and HNF1Α-AS1 with no 
statistical significance (Figure 2.2C). For basal P450 expression, only PXR regulated P450s, 
CYP2B6 and 3A4, were decreased, whereas CYP1A2 was increased (Figure 2.2D). Furthermore, 
induction of the PXR regulated P450s was significantly repressed by PXR knockdown compared 
to the control group, for example, CYP2B6 (3.4 fold change to 1.6 fold change in the induction 
level after PXR knockdown by PB treatment) and 3A4 (9.3 fold change to 1.4 fold change in the 
induction level after PXR knockdown by PB treatment and 4.7 fold change to 1.6 fold change in 








Figure 2. 2.  Changes of gene expression by PXR knockdown. 
(A) Suppression of PXR expression in both mRNA (left) and protein (right) levels by siRNA 
transfection into HepaRG cells. (B) Expression of the selected transcription factors after PXR 
knockdown. (C) Expression of HNF4α -AS1 or HNF1α -AS1 after PXR knockdown. (D) 
Expression of the selected P450s at basal levels after PXR knockdown. (E) Expression of the 
selected P450s at induced levels with treatment of either phenobarbital (PB) or rifampicin (RIF) 
after PXR knockdown. The sample size for each group is n = 3. Data are shown as mean ± SD. *p 




2.3.3 Impact on Regulation of P450s by Knockdown of HNF1α 
Next, the role of HNF1α was studied in an experiment with the same design as CAR and PXR. 
Transfection of siHNF1α resulted in a decrease of 54% in HNF1α mRNA level and a decrease of 
59% in HNF1α protein level (Figure 2.3A). HNF1α knockdown also repressed mRNA expression 
of PXR and CAR, while increased mRNA expression of AHR. The expression of HNF4α was not 
affected (Figure 2.3B). For lncRNAs, the expression of HNF4α -AS1 was not affected (Figure 
2.3C). However, HNF1α knockdown caused a decrease of 85% of HNF1α -AS1 expression as 
shown in Figure 2.3C. HNF1α knockdown also affected the expression of multiple P450s in both 
basal and induction levels. Basal expression of CYP2B6, 2C8, 2C9, 2C19, 2E1, and 3A4 showed 
decreases with statistical significance (Figure 2.3D). The expression of CYP2B6 and 3A4 was still 
induced by treatment with either PB or RIF, but in a much lower fold compared to the control 
group. Furthermore, the induction of CYP2C8, 2C9, and 2C19 was completely abolished by 








Figure 2. 3.  Changes of gene expression by HNF1 knockdown. 
(A) Suppression of HNF1 expression in both mRNA (left) and protein (right) levels by siRNA 
transfection into HepaRG cells. (B) Expression of the selected transcription factors after HNF1 
knockdown. (C) Expression of HNF4-AS1 or HNF1-AS1 after HNF1 knockdown. (D) 
Expression of the selected P450s at basal levels after HNF1 knockdown. (E) Expression of the 
selected P450s at induced levels with treatment of either phenobarbital (PB) or rifampicin (RIF) 
after HNF1 knockdown. The sample size for each group is n = 3. Data are shown as mean ± SD. 




2.3.4 Impact on Regulation of P450s by Knockdown of HNF4α 
Cells transfected with siHNF4α showed 60% less expression of HNF4α mRNA and almost 
depleted expression of HNF4α protein (Figure 2.4A). In the analysis of the selected transcription 
factors, expression levels of HNF1α, PXR, and CAR all decreased, while AHR expression 
increased with HNF4α knockdown (Figure 2.4B). Expression of both lncRNAs was almost 
depleted with approximately a decrease of 90% in HNF4α-AS1 expression and a decrease of 63% 
in HNF1α-AS1 expression (Figure 2.4C). HNF4α knockdown also decreased basal expression of 
CYP2B6, 2C8, 2C9, 2C19, 2E1, and 3A4, but to a much greater extent than HNF1α knockdown 
(Figure 2.4D). P450 induction by treatment with PB or RIF was also largely diminished by HNF4α 








Figure 2. 4.  Changes of gene expression by HNF4 knockdown. 
(A) Suppression of HNF4 expression in both mRNA (left) and protein (right) levels by siRNA 
transfection into HepaRG cells. (B) Expression of the selected transcription factors after HNF4 
knockdown. (C) Expression of HNF4-AS1 or HNF1-AS1 after HNF4 knockdown. (D) 
Expression of the selected P450s at basal levels after HNF4 knockdown. (E) Expression of the 
selected P450s at induced levels with treatment of either phenobarbital (PB) or rifampicin (RIF) 
after HNF4 knockdown. The sample size for each group is n = 3. Data are shown as mean ± 




2.3.5 Impact on Regulation of P450s by Knockdown of HNF1α-AS1 
To study the role of the lncRNAs in the regulatory network in control of expression of P450s, 
HepaRG cells were first transfected with siRNA or shRNA to knock down HNF1α-AS1. As shown 
in Figure 2.5A, siRNA and shRNA transfection decreased HNF1α -AS1 expression by 
approximately 40% and 75%, respectively. In terms of transcription factors, HepaRG cells 
transfected with siHNF1α-AS1 only showed decreased mRNA expression of CAR, while HNF1α, 
HNF4α, PXR, and AHR remained unchanged. However, HepaRG cells transfected with 
shHNF1α-AS1 showed decreased mRNA expression in all examined transcription factors, among 
which HNF4α, HNF1α, and AHR had only a minor decrease (15%, 28%, and 22%, respectively), 
while CAR and PXR had a major decrease (55% and 65%, respectively) (Figure 2.5B). Expression 
of lncRNA HNF4α -AS1 was only affected by shHNF1α-AS1 transfection with a decrease of 33% 
Figure 2.5C). Basal expressions of several P450s were also affected by HNF1α-AS1 knockdown. 
HepaRG cells transfected with siHNF1α-AS1 showed an increase in CYP1A2 expression and a 
decrease in CYP2E1 expression with statistical significance, companied with minor decreases in 
CYP2B6, 2C8, and 2C9 (Figure 2.5D). HepaRG cells transfected with shHNF1α-AS1 showed 








Figure 2. 5. Changes of gene expression by HNF1α-AS1 knockdown. 
(A) Suppression of HNF1-AS1 expression by siRNA or shRNA transfection into HepaRG 
cells. (B) Expression of the selected transcription factors after HNF1-AS1 knockdown. (C) 
Expression of HNF4-AS1 after HNF1-AS1 knockdown. (D) Expression of the selected P450s 
at basal levels after HNF1-AS1 knockdown. The sample size for each group is n = 3. Data are 
shown as mean ± SD. *p < 0.05, **p < 0.01, and ***p < 0.001 versus control in two-tailed 




2.3.6 Impact on Regulation of P450s by Knockdown of HNF4α-AS1 
The role of HNF4α-AS1 in the regulatory network in control of expression of P450s was also 
studied in HepaRG cells transfected with siRNA targeting HNF1α -AS1. HNF4α -AS1 expression 
was decreased approximately 70% by siRNA transfection (Figure 2.6A). Next, the expressions of 
the selected transcription factors were determined. Expression of HNF4α and HNF1α were 
increased slightly and expression of CAR was increased dramatically after HNF4α-AS1 
knockdown, while expression of AHR was decreased with statistical significance (Figure 2.6B). 
Knockdown of HNF4α -AS1 did not affect expression of HNF1α -AS1 (Figure 2.6C). mRNA 
expressions of the selected P450s were measured. As shown in Figure 2.6D, all selected P450s, 










Figure 2. 6. Changes of gene expression by HNF4-AS1 knockdown. 
(A) Suppression of HNF4-AS1 expression by siRNA transfection into HepaRG cells. (B) 
Expression of the selected transcription factors after HNF4-AS1 knockdown. (C) Expression of 
HNF1-AS1 after HNF4-AS1 knockdown. (D) Expression of the selected P450s at basal levels 
after HNF4-AS1 knockdown. The sample size for each group is n = 3. Data are shown as mean 





Transcription factors play a prominent role in the regulation of P450 expression [193,196]. In 
the present study, we studied the functions of CAR, PXR, HNF1α, and HNF4α. In addition, 
HNF1α-AS1 and HNF4α-AS1, which are the neighborhood lncRNAs of HNF1α and HNF1α, were 
also selected to test their roles in the regulation of P450 expression. Efficient knockdown of target 
genes was performed by siRNA or shRNA transfection into HepaRG cells. The effects on 
transcription of the selected transcription factors, lncRNAs, and drug-metabolizing P450 genes 
were measured by quantitative RT-PCR.   
CAR and PXR have been reported to regulate expression of specific P450 subfamilies of 
CYP2Bs and CYP3As, respectively [200,201].  In our experiment, knockdown of CAR or PXR 
only showed a minor effect on expression of other transcription factors or lncRNAs (Figure 2.1B, 
1C, 2B, and 2C). Knockdown of CAR decreased basal and phenobarbital-induced expression of 
CYP2B6 (Figure 2.1D and 1E), whereas knockdown of PXR reduced basal and rifampicin-induced 
expression of CYP3A4 (Figure 2.2D and 2E) in HepaRG cells. In addition, CAR knockdown also 
showed a minor effect on phenobarbital-induced expression of CYP2C and 3A families (Figure 
2.1E), while PXR knockdown showed slightly diminished phenobarbital-induced expression of 
CYP2B and 2C families (Figure 2.2E).  
The role of HNF1α in the regulation of multiple hepatic expressions of P450s has previously 
been studied in an HNF1α -deficient mouse model [32]. Our data showed that HNF1α knockdown 
in HepaRG cells led to decreased expression of PXR and CAR, while increased expression of AhR. 
Knockdown of HNF1α in HepaRG cells also decreased the basal mRNA levels of CYP2B6, 2C8, 
2C9, 2C19, 2E1, and 3A4, while increased mRNA level of CYP1A2 (Figure 2.3D). Compared 
with HNF1α-deficient mice data, we observed a similar regulation pattern in CYP2C and 2E 
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subfamilies and an opposite regulation pattern in CYP1A, 2B, and 3A subfamilies. Furthermore, 
the phenobarbital- and rifampicin-induced levels of the most examined P450s were also greatly 
inhibited by HNF1α knockdown, where the inhibition of CYP2B and 3A subfamilies might be at 
partially due to decreased expression of CAR and PXR (Figure 2.3E).   
The role of HNF4α in the regulation of hepatic P450 genes has been studied in several species. 
In HepaRG cells, we found that HNF4α knockdown decreased the expression of HNF1α, CAR, 
and PXR, while increased expression of AhR (Figure 2.4B). Similar to HNF1α knockdown, 
HNF4α knockdown led to decreased expression of CYP2B6, 2C8, 2C9, 2C19, 2E1, and 3A4, while 
increased the CYP1A2 expression (Figure 2.4D). In addition, the phenobarbital- and rifampicin-
induced P450 expression was greatly inhibited, which might be partially contributed by decreased 
CAR and PXR (Figure 2.4E).   
In the current study, we found that knockdown of HNF1α and HNF4α was able to decrease the 
expression of PXR and CAR. This agreed with previous data showing HNF4α crosstalk with PXR 
and CAR in the regulation of P450 expression [217,218]. In addition, HNF4α has also been 
reported to directly regulate expression of PXR and CAR and sequential induction of P450s 
through these two nuclear receptors [202,219]. 
The interaction between HNF1α and HNF4α has been documented in several previous studies 
[203,220]. A study showed that HNF4α positively regulates HNF4α in rat hepatoma cells, 
evidenced by deleting the HNF4α binding site in the promoter region of the HNF1α gene abolished 
the promoter activity [203]. Another study showed that HNF1α was able to negatively regulate 
HNF4α, evidenced by the identification of a binding site of HNF1α in the HNF4α promoter region   
[220]. However, in the study on HNF1α -deficient mice, the expression of HNF4α was not changed 
[32]. In our result, HNF1α knockdown only had a minor effect on mRNA expression of HNF4α 
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(Figure 2.3B), which agreed with the mouse data. HNF4α knockdown decreased mRNA 
expression of HNF1α with statistical significance (Figure 2.4B), which agreed with the rat 
hepatoma cell data. Our data imply the existence of a transcription regulatory network containing 
transcription factors of HNF1α, HNF4α, and CAR/PXR in an order to control the basal and drug-
induced expression of major P450s involved in drug metabolism.  
In recent years, utilizing the encyclopedia of DNA elements (ENCODE) project, studies have 
revealed that over 70% of the human genome are capable of being transcribed into RNAs [221]. 
However, not all the transcribed primary RNAs have protein coding ability. In human, only 
approximate 2% of the transcribed RNAs are translated into proteins [42]. Other than 
housekeeping non-coding RNAs (ribosomal RNAs, transfer RNAs, and small nuclear RNAs), 
whose biological functions have been well defined, regulatory non-coding RNAs (siRNAs, 
microRNAs, and long non-coding RNAs) have recently shown to be actively involved in 
physiological regulations [210,221]. Further, lncRNAs have been shown to perform transcriptional 
regulation through interaction with transcription factors in different tissues [111,222]. 
We identified two lncRNAs as our interested target lncRNAs, HNF1α -AS1 and HNF4α -AS1, 
which are located in the neighborhood regions of the HNF1α and HNF1α genes, respectively. 
Evidence has shown that antisense lncRNAs are likely to involve in the regulatory functions of 
their neighborhood coding genes [114]. Hence, we examined the role of two selected lncRNAs in 
the regulation of P450 expression. We found that the expression of HNF1α -AS1 and HNF4α -
AS1 is largely dependent on its neighborhood transcription factors HNF1α and HNF4α 
respectively. HNF1α knockdown depleted the expression of HNF1α -AS1 without alteration of 
expression of HNF4α -AS1 (Figure 2.3C). The knockdown of HNF4α decreased expression of 
both HNF1α -AS1 and HNF4α -AS1 (Figure 2.4C). We believed that HNF4α -AS1 was dependent 
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on the expression of HNF4α and decreased expression of HNF1α after HNF4α knockdown was 
responsible for the decrease of HNF1α -AS1.  
In the lncRNA knockdown experiments, HNF1α -AS1 knockdown by siRNA and shRNA 
showed very similar regulation trends on most examined genes (Figure 2.5). Knockdown of 
HNF1α -AS1 by shRNA decreased mRNA expression of all examined transcription factors and 
basal levels of P450s as well as expression of HNF4α -AS1 (Figure 2.5B, 5C, and 5D). The effect 
of HNF1α -AS1 knockdown was very similar to HNF1α knockdown, indicating that HNF1α -AS1 
might work as a downstream co-factor of HNF1α in the regulation of other transcription factors 
and P450s. The knockdown of HNF4α-AS1 showed opposite regulatory effects on almost all 
examined genes compared to knockdown of HNF1α, HNF4α, and HNF1α -AS1 (Figure 2.6B, 6C, 
and 6D), indicating the potential inhibitory role of HNF4α -AS1 in the regulation of P450s by the 
transcription factor network. These results confirmed our hypothesis that the lncRNAs of HNF1α 
-AS1 and HNF4α -AS1 participate in the regulation of drug-metabolizing P450 enzymes.  
Even though we have observed involvement of the lncRNAs in the regulation of P450 
expression; the underlying mechanisms are still unclear. Several mechanisms in regulation of gene 
expression by lncRNAs have been identified at different levels of gene expression, including 
transcriptional and post-transcriptional regulation levels [209,223]. Generally, the regulatory roles 
of lncRNAs depend on interacting with partner molecules, such as proteins, RNAs, and DNAs 
[114]. Proteins are believed to be the major binding partners of lncRNAs due to the discovery of 
distinct protein binding domains on lncRNAs. By binding with protein molecules, lncRNAs can 
either work as scaffold molecules to promote the formation of protein complexes or work as guide 
molecules to move proteins to a specific location. Depending on which protein is recruited, 
lncRNAs can have different impacts on expression of their regulating target genes [224]. 
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Interactions between lncRNAs and other RNAs can regulate targeted RNA properties, including 
RNA stability and translation efficiency. For example, an antisense lncRNA located next to mouse 
coding gene Uchl1 is able to regulate the translation efficiency of UCHL1 protein through 
activation of polysomes [225]. Several specific examples have revealed the interactions between 
lncRNAs and DNAs, but whether these interactions are widespread in a genome is still unclear. 
For example, a noncoding RNA, promoter associated RNA (pRNA), has shown to mediate de novo 
methylation of its targeted DNAs by forming a DNA: RNA triplex, which can be recognized by 
DNA methyltransferases [226]. All evidence suggested that lncRNAs are associated with the 
complexity of gene regulation processes. Based on current assays, we will study how HNF1α-AS1 
and HNF4α-AS1 regulate their targeted genes and involve in the regulation network in control of 
basal and drug-induced expression of P450s in future experiments.  
In conclusion, the present study demonstrates the existence of a transcription regulatory 
network controlling the expression of P450s in HepaRG cells (Figure 2.7). Several levels of P450 
regulation can be found in the current study. HNF1α and HNF4α were regarded as the master 
regulators to all other components. HNF1α and HNF4α positively regulated the expression of their 
neighborhood lncRNAs, PXR, CAR, and tested P450s. In the next level of regulation, PXR and 
CAR were found to positively regulate the expression of specific P450s, while no regulatory effect 
was found to other tested transcription factors or lncRNAs. In terms of lncRNAs, HNF1α-AS1 and 
HNF4α-AS1 were shown to regulate PXR, CAR, and P450s, while only had minor regulatory 
effects to their neighborhood coding genes. HNF1α-AS1 was shown to positively regulate the 






Figure 2. 7. P450 regulatory network in HepaRG cells 
Red arrows indicate positive regulatory effects. Blue arrows indicated negative regulatory 
effects. The width of the arrow indicates the strength of the regulation, a thick arrow indicates 





Chapter 3. Knockdown of LncRNAs HNF1α-AS1 and 
HNF4α-AS1 Alters Susceptibility of Acetaminophen-
induced Cytotoxicity in HepaRG Cells 
 
3.1 Introduction 
Acetaminophen (APAP), or N-acetyl-p-aminophenol, is one of the most commonly used over-
the-counter drugs for its antipyretic or analgesic effects in the treatment of fever or management 
of pain [227]. APAP is a safe drug if used properly. The maximal dose of 4,000 mg per day 
suggested by the US Food and Drug Administration is considered to be safe and generally does 
not cause liver toxicity [228]. However, APAP overdose can result in severe APAP-induced liver 
injury (AILI). Previous reports have indicated that AILI is one of the most common causes of liver 
damage and acute liver failure in the United States [229,230]. Furthermore, APAP-related deaths, 
mostly caused by liver failure, are much more than those liver failure fatalities caused by all other 
prescription drugs combined [231]. Considerable efforts have been made to understand the 
mechanisms responsible for AILI in different in vivo and in vitro models. N-acetyl-p-benzoquinone 
imine (NAPQI), the active metabolite of APAP by cytochrome P450s (CYPs), has been proven to 
cause cellular stress and damage through several pathways, including induction of oxidative stress 
[232]. In this case, the metabolism of APAP by CYPs to NAPQI has been regarded as a critical 
step in the development of AILI [233].  
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CYPs are a group of heme-containing enzymes, which catalyze the metabolism of a broad 
range of endogenous compounds, environmental chemicals, and drugs [234]. The expression and 
function of CYPs are critical factors in the maintenance of human health and therapeutic efficacy 
of drugs. However, great inter-individual variability has been observed in CYP expression and 
functions as well as CYP-mediated drug metabolism [235]. Several CYP subfamily members, 
including CYP1A2, 2E1, and 3A4, have been proven to mediate biotransformation of APAP to 
NAPQI, which are important mediators for predicting AILI [236].  
Multiple regulatory factors and mechanisms are involved in the regulation of CYP expression. 
Genetic and epigenetic regulations are among the most widely studied factors contributing to 
differential metabolism of drugs among individuals [5,17,237]. Furthermore, recent studies also 
showed that several factors known to affect APAP-metabolizing CYP enzymes are able to alter 
APAP metabolism and AILI outcome [238]. However, these studies mainly focus on the roles of 
genetic polymorphisms in the CYP genes, which can only account for a small portion of the inter-
individual differences in expression of CYPs and ability to metabolize drugs [239]. More factors 
and mechanisms are needed to be discovered to fully understand this process. 
LncRNAs are RNA transcripts from non-coding genes with a length of more than 200 
nucleotides [204]. Recent studies have shown that the overwhelmingly abundant lncRNAs, 
comparing to coding RNAs, in human and other species have important functions in multiple 
physiological processes, including development, cell differentiation, and immune response [240-
243]. Increasing evidence shows that lncRNAs are also important for the metabolism processes 
[210,244]. However, how lncRNAs regulate CYP-mediated drug metabolism and the toxicological 
consequences on CYP-generated metabolites are still not fully understood. 
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Neighborhood antisense lncRNAs are a common phenomenon in multiple living organisms, 
including human [114]. Several examples have suggested that the existence of neighborhood 
antisense lncRNAs is critical for the function of their neighborhood coding genes [123,245]. 
LncRNAs hepatocyte nuclear factor 1α (HNF1α) antisense RNA 1 (HNF1α-AS1) 
and HNF4α antisense RNA 1 (HNF4α-AS1) are neighborhood antisense lncRNAs of the 
transcription factors HNF1α and HNF4α, respectively. These two lncRNAs have been reported to 
regulate mRNA levels of several CYPs (including CYP1A2, 2E1, and 3A4) in opposing manners 
in in vitro models [246,247]. Based on this observation, we hypothesize that the lncRNAs HNF1α-
AS1 and HNF4α-AS1 have opposite effects modulating AILI via alterations in APAP metabolism 
by CYPs. To test the hypothesis, transfection of small hairpin RNA (shRNA) containing vectors 
were used to knock down HNF1α-AS1 and HNF4α-AS1 in HepaRG cells, a reliable in vitro model 
to study hepatotoxicity caused by APAP [248]. Cytotoxicity generated by APAP was determined 
by several different toxicity assays, including 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay, lactate dehydrogenase (LDH) release, and 
dihydrorhodamine 123 (DHR123) staining assays. Alterations in mRNA and protein levels of 
APAP-metabolizing phase I and II enzymes were determined by quantitative real-time PCR (RT-





3.2 Materials and Methods 
 
3.2.1 Chemicals and Reagents 
HepaRG cells, HepaRG growth additives (Catalog number: ADD710), and HepaRG 
differentiation additives (Catalog number: ADD720) were obtained from Biopredic International 
(Rennes, France). William’s E Medium, collagen I coated T-25 flasks, collagen I coated 12-well 
plates, collagen I coated chamber slides, Glutamax™ supplement, Opti-MEM medium, 
Lipofectamine™ stem transfection reagent, MTT, Pierce LDH Cytotoxicity Assay Kit, and 
DHR123 were obtained from Thermo Fisher Scientific (Carlsbad, CA). A shRNA negative control 
and shRNAs targeting HNF1α-AS1 or HNF4α-AS1 were obtained from GeneCopoeia (Rockville, 
MD). APAP was obtained from Sigma-Aldrich (St. Louis, MO). An antibody against 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was purchased from Abcam (Cambridge, 
MA). Antibodies against CYP1A2 and 2E1 were purchased from Proteintech (Rosemont, IL). An 
anti-rabbit IgG antibody was obtained from Cell Signaling Technology (Danvers, MA). The 
TRIzol™ reagent was obtained from Invitrogen (Carlsbad, CA).  
 
3.2.2 Cell Culture 
HepaRG cells were cultured according to the provider’s protocol. Briefly, the HepaRG cells 
were cultured in a three-step manner. Thawed cells were firstly cultured in a HepaRG growth 
medium (William’s E Medium supplied with Glutamax™ and growth additives) for two weeks 
until cells became fully confluent. Cells were then kept in a mixture of HepaRG growth medium 
and HepaRG differentiation medium (William’s E Medium supplied with Glutamax™ and 
differentiation additives) for another week. Lastly, cells were cultured in a HepaRG differentiation 
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medium for one more week when cells were fully differentiated. Cells were incubated in a 
humidified cell incubator at 37°C with 5% CO2.  
 
3.2.3 shRNA Transfection 
To generate lncRNA loss-of-function HepaRG models, plasmid vector-containing shRNAs 
with different targets were designed and purchased from GeneCopoeia (Rockville, MD, USA). 
The transfection processes were performed according to a previous study with minor modifications 
[249]. Briefly, HepaRG cells are seeded in collagen I coated 6-well plates with a concentration of 
~50,000 cells/well. Plasmid transfection was performed when the cells reached to ~90% 
confluence. Liposomes were prepared by mixing 1 μg shRNA-containing vector in 50 µL Opti-
MEM medium with 5 µl Lipofectamine™ stem transfection reagent in 50 µl Opti-MEM. After 
incubation for 20 minutes at room temperature, the DNA-lipid complexes were added to HepaRG 
cells. A puromycin selection (3 μg/ml) was performed after the transfection to select transfected 
cells. Cells were then cultured to a fully differentiated status. 
 
3.2.4 APAP Treatment 
Differentiated HepaRG cells (transfected with shNC, shHNF1α-AS1, or shHNF4α-AS1) were 
seeded into collagen-I coated 96-well plates with a density of 20,000 cells/well. Cells were 
incubated overnight for attachment before treatment. Cells were then treated with 0, 10, 30, or 100 






3.2.5 MTT Assay 
Cell viability was measured by the MTT assay according to the manufacturer’s protocol. 
Briefly, after APAP treatment, 20 µL of MTT solution (4 mg/ml) was added to each well and the 
plates were incubated for 3.5 h in a 37°C incubator. After incubation, the remaining solution was 
removed carefully from the plates and 100 µL of dimethyl sulfoxide (DMSO) was added to each 
well to dissolve formed crystal. The plates were then agitated on an orbital shaker for 15 min for 
completed dissolution. Absorbance of solution was then measured at 570 nm with a 
spectrophotometric plate reader. Cell viability was calculated as percentage of the control group. 
 
3.2.6 LDH Assay 
Cell damage was measured by the LDH release assay according to the manufacturer’s protocol. 
Same as the MTT assay above, one set of cells serving as a positive control was added with 10 µL 
lysis buffer after APAP treatment, while another set of cells was added with 10 µL sterile water. 
Cells were then incubated for 45 min in a cell incubator. After incubation, 50 µL supernatant of 
each sample was transferred into a new 96-well flat bottom plate. A reaction mixture (50 µL) was 
then added to each sample followed by gentle mixing. Plates were then incubated at room 
temperature for 30 min protected from light. After a final incubation, 50 µL of the stop solution 
were added to each sample with gentle mixing. Absorbance at 490 and 680 nm was measured with 
a spectrophotometer and LDH activity was calculated as the difference in absorbance between 680 
and 490 nm. The level of cell damage was represented by the ratio of LDH activities between a 





3.2.7 DHR123 Staining 
Oxidative stress in HepaRG cells after APAP treatment was measured by DHR123 staining. 
Differentiated HepaRG cells (transfected with shNC, shHNF1α-AS1, or shHNF4α-AS1) were 
seeded into collagen-I coated chamber slides with a density of 100,000 cells/well and incubated 
overnight for attachment. Cells were then treated with 10 mM of APAP in a 500-µL culturing 
medium for 24 h. After the treatment, the medium was removed and cells were rinsed once with 
PBS. Diluted DHR123 solution (5 µM) was then added to each well and plates were incubated for 
45 min with protection from light. After incubation, the DHR123 solution was replaced with PBS. 
Images of fluorescent stained cells at ×400 magnification were taken using an EVOS Fluorescence 
Microscope (Thermo Fisher Scientific, Carlsbad, CA). Quantification of fluorescence signals was 
performed with ImageJ software (NIH). 
 
3.2.8 RNA Isolation and Quantitative Real-Time PCR (RT-PCR) 
Total RNAs were isolated from HepaRG cells using a TRIzol™ reagent according to the 
manufacturer’s protocol. RNA concentration was measured by a Nano Drop spectrophotometer 
(Nano Drop Technologies, Wilmington, DE) at 260 nm and RNA integrity was evaluated using an 
Agilent 2,200 Tape Station (Agilent Technologies, Santa Clara, CA). One µg of total RNAs was 
subjected to cDNA synthesis using an iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, 
Hercules, CA). RT-PCR was performed using a CFX96™ Real-Time System (Bio-Rad 
Laboratories, Hercules, CA) with the primer sequences shown in Table 3.1. RNA or mRNA levels 
of GAPDH, HNF1α-AS1, CYP1A2, 2E1, 3A4, SULT1A1, UGT1A1, 1A9, GSTP1, and GSTT1 
were measured using an iTaq™ Universal SYBR® Green Supermix (Bio-Rad Laboratories, 
Hercules, CA). RNA level of HNF4α-AS1 was measured by a TaqMan™ Gene expression assay 
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(Life Technologies, Carlsbad, CA). Relative mRNA levels were determined by normalizing 
examined gene expression against mRNA level of GAPDH using the 2-ΔΔCt method.  
 
3.2.9 Protein Sample Preparation and Western Blotting 
Cell lysates were prepared from HeapRG cells cultured in a collagen-I coated T-25 flask with 
a RIPA buffer (supplied with protease inhibitor cocktail). Protein concentrations were determined 
using a Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA). Eighty µg of protein was loaded and 
run on a polyacrylamide gel using a Mini-PROTEAN Tetra System (Bio-Rad Laboratories, 
Hercules, CA). Proteins were then transferred onto PVDF membranes and blocked in 5% bovine 
serum albumin (BSA) for 1 h. After blocking, membranes were incubated with primary antibodies 
diluted in 2.5% BSA (anti-GAPDH 1:4,000, anti-CYP1A2 1:1,000, and anti-CYP2E1 1:1,000) 
overnight. Then membranes were incubated in an anti-rabbit IgG antibody (1:5,000) diluted in 2.5% 
BSA. Protein bands were visualized using a ChemiDoc MP Imaging System (Bio-Rad, Hercules, 
CA).  
 
3.2.10 Statistical Analysis 
The data are shown as mean ± SD (standard deviation). A two-tailed unpaired Student’s t test 
was used to determine the significance of differences in lncRNA expression after shRNA 
transfection. A two-way ANOVA followed by Tukey’s test was used to determine the significance 
of differences in the MTT and LDH assays. A one-way ANOVA followed by Dunnett's test was 
used to determine the significance of differences in the DHR123 staining and RT-PCR results. 
Statistical analyses were performed using Prism7, version 7.01 from GraphPad Software, Inc. (La 
Jolla, CA, USA). Differences were regarded as statistically significant if p<0.05. 
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Table 3. 1 List of primers used for real time PCR. 
 
SYBR Primers (Integrated DNA Technologies, Coralville, IA) 
 
TaqMan™ primer (Life Technologies, Carlsbad, CA) 





Gene Primer Sequence 
GAPDH Forward 5′-GGGAGCCAAAAGGGTCAT-3′ 
Reverse 5′-GAGTCCTTCCACGATACCAA-3′ 
HNF1α-AS1 Forward 5′-TCAAGAAATGGTGGCTAT-3′ 
Reverse 5′-GCTCTGAGACTGGCTGAA-3’ 
CYP1A2 Forward 5’-CCAACGTCATTGGTGCCATG-3’ 
Reverse 5’-GTGATGTCCCGGACACTGTTC-3’ 
CYP2E1 Forward 5’-AATGGACCTACCTGGAAGGAC-3’ 
Reverse 5’-CCTCTGGATCCGGCTCTCATT-3’ 
CYP3A4 Forward 5’-GATTGACTCTCAGAATTCAAAAGAAACTGA-3’ 
Reverse 5’-GGTGAGTGGCCAGTTCATACATAATG-3’ 
SULT1A1 Forward 5’-AGGAGTTCATGGACCACAGC-3’ 
Reverse 5’-TGAAGGTGGTCTTCCAGTCC-3’ 






GSTP1 Forward 5’-TCCCCAGTGACTGTGTGTTG-3’ 
Reverse 5’-GAAGCCCCTTTCTTTGTTCA-3’ 





3.3.1 Impact on APAP-induced Cytotoxicity by Knockdown of HNF1α-AS1 and HNF4α-
AS1 
To study the roles of the lncRNAs, HNF1α-AS1 and HNF4α-AS1, in affecting the cytotoxicity 
of APAP, HepaRG cells were stably transfected with shRNAs targeting these two lncRNAs as 
well as a negative control. Several assays measuring APAP cytotoxicity, including MTT, LDH 
release, and HDR123 staining assays were performed. Knockdown of HNF1α-AS1 and HNF4α-
AS1 by shRNA transfection in HepaRG cells yielded a decrease in their RNA levels to 0.41-fold 
(95% confidence interval CI = 0.24 to 0.58, ***p<0.001) and 0.46-fold (CI = 0.23 to 0.71, 
**p<0.01) comparing to their control groups (cells transfected with shNC), respectively, which is 
indicative of successful knockdown (Figure 3.1A and 1B). Cells with stable lncRNA knockdown 
were then treated with different concentrations of APAP for the assessment of cytotoxicity. 
The MTT assay was performed to test cell viability after APAP challenge. Cells were treated 
with different concentrations of APAP (0, 10, 30, or 100 mM) for 24 h. Cell viability was 
normalized to the control group (cells transfected with shNC receiving no APAP treatment). As 
shown in Figure 3.2A, knockdown of HNF1α-AS1 and HNF4α-AS1 did not alter cell viability in 
non-APAP challenged cells. However, when treated with APAP at concentrations of 10 or 30 mM, 
cells with lncRNAs knockdown showed a differential susceptibility to APAP toxicity. Specifically, 
knockdown of HNF1α-AS1 led to increases in cell viability when treated with APAP at 
concentrations of 10 or 30 mM, while the opposite was observed in HNF4α-AS1 knockdown cells, 
where the cell viability was lower at the same APAP concentrations (Figure 3.2A). These results 





Figure 3. 1. Knockdown of lncRNAs HNF1α-AS1 and HNF4α-AS1 in HepaRG cells. 
HepaRG cells during a growth period were stably transfected with a negative control shRNA 
(shNC), shRNAs targeting HNF1α-AS1 (shHNF1α-AS1), or shRNAs targeting HNF4α-AS1 
(shHNF4α-AS1). Relative expression of HNF1α-AS1 and HNF4α-AS1 was measured by RT-PCR. 
The changes of relative mRNA expression compared to the shNC controls were calculated using 
the 2-∆∆t method after normalization with GAPDH. Data are shown as mean ± SD (n = 3) and 





Figure 3. 2. Changes of APAP-induced cytotoxicity by knockdown of HNF1α-AS1 and HNF4α-
AS1 in HepaRG cells. 
(A) Cell viability evaluated by the MTT assay after APAP treatment at concentrations of 0, 10, 30, 
and 100 mM. (B) Cell damage assessed by the LDH release assay after APAP treatment. Data are 
shown as mean ± SD (n = 3) and analyzed by a two-way ANOVA followed by Tukey’s test. 




At 100 mM APAP, which is a highly toxic concentration, no differences in cytotoxicity were 
observed and cell viability was low among all three groups of HepaRG cells. 
The LDH release assay was used for detecting extent of cell damage. Aside from cell death, 
damage of living cells was another parameter to assess drug-induced cytotoxicity. As expected, 
Figure 3.2B shows no increases in LDH release after knockdown of HNF1α-AS1 and HNF4α-
AS1 when not challenged with APAP. Increases in LDH release were observed in HNF4α-AS1 
knockdown cells treated with 10 or 30 mM APAP. By contrast, HNF1α-AS1 knockdown cells 
treated with the same concentrations of APAP had lower LDH values in comparison to shNC cells. 
Similar to the results of the MTT assay, no differences in LDH release values were observed at 
100 mM APAP in all three groups of HepaRG cells.  
Overproduction and accumulation of reactive oxygen species (ROS) and induction of oxidative 
stress is one of the main features for AILI. Figure 3.3 shows the analysis of ROS production by 
DHR123 staining. Under normal conditions, no fluorescence was detected in any of the groups of 
cells (data not shown). However, with APAP treatment, differences in fluorescent intensity were 
observed. Positive stained cells, indicative of ROS accumulation, were observed in all three groups 
of cells exposed to 10 mM APAP (Figure 3.3A). Quantification results (Figure 3.3B) showed that 
cells with HNF4α-AS1 knockdown had 1.64-fold (CI =1.36 to 2.02, **p<0.01) higher fluorescent 
intensity comparing to the control group (cells transfected with shNC receiving 10 mM APAP 
treatment), while cells with HNF1α-AS1 knockdown led to a  0.47-fold (CI =0.36 to 0.59, *p<0.05)  
lower fluorescent intensity. Notably, only metabolically active hepatocyte-like cells, which 
express CYP enzymes, were stained positively by DHR123, while no fluorescence was detected 




This observation indicates that the production of ROS co-localizes to cells where CYP-
mediated bioactivation of APAP occurs. The cells with HNF4α-AS1 knockdown showed an 
observable brighter green fluorescence compared to other groups, indicating higher levels of ROS, 
which is consistent with higher toxicity in those cells. By contrast, fewer positive stained cells and 
dimmed green fluorescence were detected in HNF1α-AS1 knockdown cells, indicating lower 
levels of ROS, which is also in agreement with the higher tolerance of these cells to APAP.  
The results from the cytotoxicity assays performed here provided strong evidence that 
knockdown of lncRNA HNF1α-AS1 or HNF4α-AS1 altered cell susceptibility to APAP 
cytotoxicity. The absence of HNF4α-AS1 increased susceptibility to APAP-induced cytotoxicity, 







Figure 3. 3. Changes of APAP-induced cytotoxicity viewed by DHR123 staining in HepaRG cells 
with knockdown of lncRNAs HNF1α-AS1 and HNF4α-AS1. 
(A) Quantification of fluorescent intensity in different group of cells after treated with 10 mM 
APAP. (B) The representative images are shown with green fluorescence in hepatocyte-liver cells. 
Bar = 200 µM.  Data are shown as mean ± SD and analyzed by a one-way ANOVA analysis 
followed by Dunnett's test. *p<0.05, **p<0.01, and ***p<0.001 versus the shNC controls 




3.3.2 Impact on Metabolic Pathways of APAP by Knockdown of HNF4α-AS1 and 
HNF1α-AS1 
To determine how knockdown of HNF1α-AS1 and HNF4α-AS1 affects APAP-induced 
cytotoxicity, the enzymes involved in the metabolic pathways of APAP were examined. As shown 
in Figure 3.4, APAP is metabolized by several phase I and II enzymes, whose combined functions 
ultimately determine cytotoxicity outcome. NAPQI, the toxic metabolite, is produced by CYP-
mediated bioactivation of APAP. The major CYPs involved in this process are CYP1A2, 2E1, and 
3A4. Several phase II enzymes, including SULT1A1, UGT1A1, and 1A9, are also able to 
biotransform APAP, forming non-toxic APAP-conjugates. Furthermore, NAPQI can be detoxified 
by reacting with cellular glutathione, mediated by GSTP1 and GSTT1. The mRNA levels of these 
genes were measured in HNF4α-AS1 and HNF1α-AS1 knockdown as well as control shNC 
HepaRG cells. As shown in Figure 3.5A, knockdown of HNF1α-AS1 and HNF4α-AS1 affected 
the mRNA levels of all selected APAP-metabolizing CYP genes. Knockdown of HNF1α-AS1 
repressed mRNA levels of all CYP genes examined. Specifically, HNF1α-AS1 knockdown 
repressed mRNA levels of CYP1A2 to 0.71-fold (CI = 0.61 to 0.81, *p>0.05), CYP2E1 to 0.35-
fold (CI = 0.31 to 0.39, **p<0.01), and CYP3A4 to 0.31-fold (CI = 0.0052 to 0.61, *p<0.05) 
comparing to the control group (cells transfected with shNC). By contrast, knockdown of HNF4α-
AS1 induced mRNA levels of CYP1A2 by 1.3-fold (CI = 0.38 to 2.22, p>0.05), CYP2E1 by 1.95-
fold (CI = 1.27 to 2.63, ***p<0.001), and CYP3A4 by 1.9-fold (CI = 1.00 to 2.81, **p<0.01) 
comparing to the control group. These changes were further confirmed by analysis of protein 
abundance by Western blots. As shown in Figure 3.5B, the pattern of protein-level changes for 
CYPs is similar to that of mRNA expression. Collectively, these data indicate that lncRNAs 
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HNF1α-AS1 and HNF4α-AS1 are involved in the regulation of functional activity of 
biotransformation pathways for APAP, ultimately impacting APAP-induced cytotoxicity. 
HNF4α-AS1 knockdown produced no changes in mRNA levels of selected phase II enzymes, 
including SULT1A1, UGT1A1, and 1A9 (Figure 3.6A). The mRNA levels of SULT1A1 and 
UGT1A9 was decreased by knockdown of HNF1α-AS1 to 0.64-fold (CI = 0.48 to 0.80, *p<0.05) 
and 0.72-fold (CI = 0.59 to 0.85, *p<0.05) comparing to the control group, respectively, while no 
changes in the mRNA level of UGT1A1 was found. For GSTs, the mRNA levels of GSTT1 were 
comparable among all three groups of cells. Even though the decreases in mRNA levels of GSTP1 
by knockdown of both HNF1α-AS1 and HNF4α-AS1 were detected (Figure 3.6B), considering 
the expression level of GSTP1 in HepaRG cells is very low (Cq value around 35, data not shown), 
these changes were not believed to cause major changes in APAP metabolism and cytotoxicity. 
Taken together, these results indicate that the changes in mRNA and protein levels of CYP 
enzymes by knockdown of HNF1α-AS1 and HNF4α-AS1 are the most likely mechanisms for the 














Figure 3. 5. Impact on expression of APAP-metabolizing phase I enzymes in HepaRG cells with 
knockdown of HNF1α-AS1 and HNF4α-AS1. 
(A) Relative mRNA expression of CYP1A2, 2E1, and 3A4 was measured by RT-PCR. The 
changes of relative mRNA expression compared to the shNC controls were calculated using the 2-
∆∆t method after normalization with GAPDH. Data are shown as mean ± SD (n = 3) and analyzed 
by a one-way ANOVA analysis followed by Dunnett's test. Three separate one-way ANONAs 
were run. *p<0.05, **p<0.01, and ***p<0.001 versus the shNC controls. (B) Protein expression 









Figure 3. 6. Impact on expression of APAP-metabolizing phase II enzymes in HepaRG cells with 
knockdown of HNF1α-AS1 and HNF4α-AS1. 
(A) Relative mRNA expression of SULT1A1, UGT1A1, and 1A9 was measured by RT-PCR. 
(B) Relative mRNA expression of GSTP1 and GSTT1 was measured by RT-PCR. The changes 
of relative mRNA expression compared to the shNC controls were calculated using the 2-∆∆t 
method after normalization with GAPDH. Data are shown as mean ± SD (n = 3) and analyzed by 
a one-way ANOVA analysis followed by Dunnett's test. Three ANOVAs for the top panel; two 




Regulation of transcription factors including HNF1α and HNF4α, either by gene edition 
techniques or endogenous miRNAs, has been reported to affect cellular response to APAP-induced 
cytotoxicity [250-252]. The current study also proves that the neighborhood antisense lncRNAs 
HNF1α-AS1 and HNF4α-AS1 also affect APAP-induced cytotoxicity independently. The 
manipulation of expression of HNF1α-AS1 and HNF4α-AS1 alone is unable to affect expression 
of HNF1α and HNF4α as described in our previous studies [246,253], but is able to alter the mRNA 
and protein levels of APAP-metabolizing CYP enzymes and downstream APAP-induced 
cytotoxicity in HepaRG cells. These results suggest several critical features of the lncRNAs in the 
regulation of CYP expression and functions. Firstly, these lncRNAs work as downstream factors 
to regulate the CYPs together with the transcription factors of HNF1α and HNF4α. Indeed, several 
studies have suggested that the RNA levels of lncRNAs HNF1α-AS1 and HNF4α-AS1 are 
controlled by HNF1α and HNF4α [169,246,247]. In addition to directly binding to the CYP genes, 
the transcription factors HNF1α and HNF4α may also regulate CYP expression indirectly through 
their neighborhood lncRNAs. Secondly, the lncRNAs have distinct functions in the regulation of 
their target genes. As showed here and in our previous studies, knockdown of HNF1α-AS1 and 
HNF4α-AS1 generated opposing effects on the expression of several CYPs at both the mRNA and 
protein levels, which correlated well with contrasting effects on APAP-induced cytotoxicity. This 
phenomenon indicates that the lncRNAs HNF1α-AS1 and HNF4α-AS1 may be involved in a 
dynamic interrelated regulation of CYPs, where both upregulation and downregulation can occur. 
Generally, the binding of transcription factors to their target genes promotes gene expression, 
leading to upregulation of gene expression, which is the case for induction of some CYPs by 
activation of the pregnane X receptor (PXR) or constitutive androstane receptor (CAR) [254]. 
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However, how altered expression of CYPs returns to normal basal levels and whether negative 
feedback loops contribute to the regulation of CYP genes remain largely unknown. The roles of 
lncRNAs HNF1α-AS1 and HNF4α-AS1, which have opposing effects on the regulation of CYP 
expression in controlling CYP functions under different physiological conditions, need to be 
addressed in future studies. Activation of some nuclear receptors, such as PXR and CAR, has been 
reported to affect AILI [255,256]. Expression of PXR or CAR can also been affected by alterations 
of lncRNAs HNF1α-AS1 or HNF4α-AS1 [246]. These lncRNAs may regulate expression of CYPs 
and affect susceptibility to AILI through indirect alterations of PXR or CAR, but this assumption 
needs to be confirmed in a future study. 
LncRNAs need cofactors to perform their functions in gene regulation. Studies have shown 
that lncRNAs are able to interact with other molecules, such as DNA, RNA, and proteins, to 
perform functions as signaling, decoys, guides, and scaffolds [94]. Identifying what molecules are 
able to interact with lncRNAs is a critical step to understand how lncRNAs perform their 
regulatory functions. One study has showed that HNF1α-AS1 is able to directly interact with 
miRNA and regulates proliferation and invasion of non-small cell lung cancer (NSCLC) cells 
[172]. LncRNA HNF1αOS1, a neighborhood antisense lncRNA of mouse Hnf1α gene, has been 
shown to interact with enhancer of zeste homolog 2 (EZH2) in mouse liver by RNA 
immunoprecipitation sequencing [257]. EZH2 is a catalytic subunit of the polycomb repressive 
complex 2, which mediates the formation of tri-methylation at histone H3 lysine 27 [258,259]. 
This evidence suggests that lncRNAs HNF1α-AS1 and HNF4α-AS1 may regulate CYP expression 
through multiple mechanisms by interacting with different types of molecules. Identification of 
molecules, mainly miRNAs or proteins, binding to HNF1α-AS1 and HNF4α-AS1, is one of our 
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current research interests to uncover the molecular mechanisms of HNF1α-AS1- and HNF4α-AS1-
mediated regulation of CYP expression.  
LncRNAs should be considered as novel factors predicting drug metabolism and cytotoxicity. 
By generating loss-of-function cell models, the current study has suggested that expression of 
lncRNAs HNF1α-AS1 and HNF4α-AS1 is important for APAP-induced cytotoxicity. Notably, in 
the correlation study performed by Wang and her colleagues using human liver samples, results 
do not only show that expression levels of HNF1α-AS1 are positively correlated to several CYPs, 
but also pointed out that HNF1α-AS1 is expressed at different levels among individuals [247]. 
Besides the well-known factors that regulate CYP-mediated drug metabolism, which have been 
shown to impact clinical outcomes of drug treatment, expression and function of CYP-regulating 
lncRNAs should be also counted as an additional factor [17,239].  
Multiple mechanisms are able to regulate the expression of lncRNAs. The NCBI database of 
human single nucleotide polymorphisms (SNPs) has listed thousands of SNPs existing in the 
HNF1α-AS1 and HNF4α-AS1 genes (https://www.ncbi.nlm.nih.gov/snp/), which might be 
responsible for the inter-individual variations in the expression of these lncRNAs. Multiple studies 
have suggested that lncRNAs are differentially expressed under disease conditions, including 
cancer, which also suggest that lncRNAs can be affected and expressed differently for a same 
individual at different times or conditions [260]. However, no studies have been performed to 
determine how SNPs in these genes affect expression or function of HNF1α-AS1 and HNF4α-AS1 
or their downstream-regulated genes. More future studies are urgently needed to address these 
knowledge gaps in their clinical relevance for drug metabolism and cytotoxicity.  
In the current research project, HepaRG was used as an experimental model to study the roles 
of lncRNA in AILI. The hepatoma derived HepaRG cell line has been widely used as a new in 
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vitro model in the study of liver functions due to its high expression levels of drug metabolizing 
enzymes and transporters [214,261]. However, several limitations still exist in HepaRG cell model. 
The differentiated HepaRG cells are composed of both hepatocyte-like cells, which act similar to 
primary hepatocytes, and cholangiocyte-like cells, which act similar to epithelial cells and do not 
respond to APAP treatment. When harvesting samples from differentiated HepaRG cells, it is 
difficult to separate these two types of cells, which will ultimately affect the experimental 
outcomes. Secondary, several SNPs have been identified in HepaRG cells, including CYP2D6, 
OATP1B1, and MRP2 genes, which may lead to dysfunctions of these proteins. The human 
primary hepatocytes, which is regarded as the “gold standard model” for in vitro metabolism and 
toxicity studies will be used in the future to validate our findings in HepaRG cells.  
In conclusion, the present study demonstrates that lncRNAs HNF1α-AS1 and HNF4α-AS1 are 
able to alter APAP-induced cytotoxicity in HepaRG cells with opposite effects, primarily by 











Chapter 4.  LncRNA in P450 induction by rifampicin 
 
4.1 Introduction 
One of the special characteristics for some P450 enzymes, but not all P450s, this that their 
expression can be induced under some circumstances, including drug treatment [262]. This 
phenomenon is believed to be a dose-dependent adaptive response of the drug-metabolizing 
system, which is likely to be evolved to protect against the accumulation of xenobiotics or toxicants 
[199]. Induction of P450s usually leads to increased detoxification of xenobiotics, but it also might 
lead to the formation of active or toxic metabolites occasionally. 
One major concern of P450 induction is that it might lead to drug-drug interactions (DDIs). By 
definition, DDIs refer to the phenomenon where the administration of one drug alters the 
therapeutic efficacy or adverse effects of another drug taken concurrently. DDIs might lead to 
significant variations in the drug response or toxicity in patients who are taking several drugs 
simultaneously. However, with the prevalence of chronic diseases, there is an increasing number 
of patients who are on polypharmacy, where multiple drugs are given to treat various diseases 
[263]. Drugs, which can induce the expression of certain P450s via the upregulation of gene 
transcription activity, may affect the metabolism of the substrate by the induced P450s. If a second 
drug, or called a victim drug, is administrated at the same time with the P450 inducer drug, DDI 
is likely to happen, leading to an alteration in the efficacy or toxicity of the victim drug. There is 
an increase of evidence showing that P450 inducing drugs and DDIs have critical impacts on the 
therapeutic effect and safety of clinical drug usages [264].  
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Rifampicin (RIF) is an antibiotic, which is widely used in the treatment of gram-positive 
bacteria, including mycobacteria. RIF is also used in combination with other drugs, including 
isoniazid, pyrazinamide, and streptomycin, in the treatment of tuberculosis [265,266]. Back in 
1972, RIF was first identified as a P450 inducer [267]. This effect of RIF was later found to affect 
the clearance of several other therapeutic agents, for example, the use of RIF at 600 mg/day was 
reported to cause a 3-fold increase in the clearance of propranolol [268]. In later studies, RIF was 
found to induce the expression of several P450 isoforms, including CYP1A2, 2C9, 2C19, and 
3A4 [269]. Nowadays, RIF related DDIs and models to predict DDIs have been reported and 
summarized to help the improvement of safety in clinical practice [270-272].  
The molecular mechanism in RIF-mediated P450 induction is better understood now. RIF was 
identified as a ligand for transcription factor PXR. PXR was a key transcription factor, which could 
activate several hepatic genes involved in drug metabolism [273]. Upon activation, PXR activates 
the transcription of several P450s by binding to the response element in the promoter region 
[194,274]. PXR was reported to be important for the induction of CYP3A4, a P450 isoform 
responsible for almost one-third of clinically used drugs. One study using Pxr null mice showed 
that the expression of CYP3A11, mouse P450 relevant to human CYP3A4, was dysregulated, 
indicating an important role of PXR in CYP3A11 activation [275].  
The mechanisms of how PXR activates CYP3A4 have not been fully understood yet. Recent 
studies have demonstrated that PXR was able to bind directly to the CYP3A4 promoter and two 
PXR response elements (distant and proximal) have been identified in the promoter region of 
CYP3A4 gene. However, the molecular activities after PXR binding are still not clear. Several 
cofactors have been identified in the PXR mediated transcription activation of P450s [276]. 
Transcription factors including FOXO, HNF1α, HNF4α, and SHP have been shown to involve in 
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the CYP3A4 activation by PXR [202,277-279]. Other than transcription factors, epigenetic 
modifying enzymes were also reported to involve in the process of PXR mediated CYP3A4 
induction. Yan et al. identified that epigenetic modifications might involve in this process. They 
found that RIF treatment led to increased levels of H3K4me3, H3 acetylation, and decreased levels 
of H3K27me3 in the promoter region of CYP3A4. Knockdown of PXR not only repressed the 
induction of CYP3A4 by RIF, but also abolished the changes in histone modifications [23]. 
Another study also showed that protein arginine methyltransferase 1, a histone tail 
methyltransferase, was important for the transcriptional activation of CYP3A4 by PXR [280]. All 
these studies suggested that cofactors are critical players in transcription activation by transcription 
factors. 
However, no studies have studied whether lncRNAs are also involved in the drug induction of 
P450s by serving as cofactors. As we already established that lncRNAs were involved in basal 
expression of P450s and transcription factors, we hypothesize that lncRNAs are also involved in 
drug-induced expression of P450s. In this study, we used RIF as a model drug and tested how 




4.2 Materials and Methods 
 
4.2.1 Chemicals and Reagents 
HepaRG cells were kindly provided by Biopredic International (Rennes, France). ADD710 
growth additives and ADD720 differentiation additives were purchased from Biopredic 
International. William’s E Media (WEM), collagen I coated T-25 flasks, collagen I coated 12-
well plates, Glutamax™ Supplement, and Opti-MEM medium were obtained from Thermo 
Fisher Scientific (Carlsbad, CA). RIF was purchased from Sigma-Aldrich (St. Louis, MO). 
  
4.2.2 Cell Culture 
HepaRG cells were cultured following a protocol from Biopredic International. Briefly, a 
three-step protocol was used to generate fully differentiated HepaRG cells. Cells were first thawed 
and cultured in HepaRG growth medium (William’s E Media supplied with Glutamax™ and 
ADD710 growth additives) for two weeks in order to reach full confluence. Cells were next 
cultured in a 1:1 mixture of HepaRG growth medium and a HepaRG differentiation medium 
(William’s E Media supplied with Glutamax™ and ADD720 growth additives) for one week. In 
the last step, cells were cultured in HepaRG differentiation medium for another week to reach a 
full differentiation status. During the whole process, cells were incubated at 37°C and 5% CO2 
with the medium changed every 3 days. Fully differentiated cells were either used directly in T-25 





4.2.3 Drug Treatment 
For drug treatment, differentiated HepaRG cells were treated with 50 µM RIF, or vehicle (0.1% 
DMSO) for 24 hours. After drug treatment, cells were harvested at different time points and RNAs 
were isolated for analysis of gene expression.  
 
4.2.4 RNA Isolation and Quantitative Real-Time PCR (RT-PCR) 
Total RNAs were isolated from HepaRG cells using a TRIzol™ reagent according to the 
manufacturer’s protocol. RNA concentration was measured by a Nano Drop spectrophotometer 
(Nano Drop Technologies, Wilmington, DE) at 260 nm and RNA integrity was evaluated using an 
Agilent 2200 Tape Station (Agilent Technologies, Santa Clara, CA). One µg of total RNAs was 
subjected to cDNA synthesis using an iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories, 
Hercules, CA). Real-time PCR was performed using a CFX96™ Real-Time System (Bio-Rad 
Laboratories, Hercules, CA) with the primer sequences described in previous sections. Expression 
of GAPDH, HNF1α, PXR, HNF1α -AS1, and CYP3A4 were measured using an iTaq™ Universal 
SYBR® Green Supermix (Bio-Rad Laboratories, Hercules, CA). Relative mRNA expression 
levels were determined by normalizing examined gene expression against GAPDH expression 
using ΔΔCt method.  
 
4.2.5 Statistical Analysis 
The data are shown as mean ± SD (standard deviation).  The significance of differences 
between means was determined using a two-tailed unpaired Student’s t test. Statistical analyses 
were performed using Prism7, version 7.01 from GraphPad Software, Inc. (La Jolla, CA, USA). 





4.3.1 Alteration of PXR and CYP3A4 by Rifampicin treatment in HepaRG cells 
To study the alterations in the expression of PXR and CYP3A4 following RIF treatment, 
HepaRG cells were treated with 50 μM of RIF for 24 hours. Cells were harvested at 48 hours, 96 
hours, and 144 hours after treatment, which was 72 hours, 120 hours, and 168 hours after 
experiment start in the figures. Expression of PXR and CYP3A4 was measured by RT-PCR at 
each of the time points mentioned above.  
The expression pattern of PXR was shown in Figure 4.1A. Interestingly, the expression of 
PXR remained largely unchanged after RIF treatment for 24 hours. However, an increase in the 
expression of PXR was observed at 48, 96, and 144 hours after treatment, with 2.4-, 3-, and 2.2-
fold induction, respectively.  
As shown in Figure 4.1B, the expression of CYP3A4 was induced by 2.5-fold after 24 hours 
of RIF treatment. Forty-eight hours after treatment, CYP3A4 reached peak expression level in all 
tested time points, with an 8.3-fold induction comparing to cells treated with vehicle. The 
expression level of CYP3A4 dropped to 4.7- and 4-fold induction at 96 and 144 hours after 
treatment, respectively. These results suggested that RIF treatment was able to induce the 







Figure 4. 1. Expression of PXR and CYP3A4 after RIF treatment 
(A) Alteration in expression of PXR by RIF treatment in HepaRG cells. (B) Induction of CYP3A4 
by RIF treatment in HepaRG cells. The sample size for each group is n = 3. Data are shown as 






4.3.2 Alteration of HNF1α and HNF1α-AS1 by RIF treatment in HepaRG cells 
The expression of HNF1α and its neighborhood lncRNA HNF1α-AS1 was also measured in 
HepaRG cells treated with RIF. 
As shown in Figure 4.2A, the expression HNF1α remained largely unchanged with only a 1.4-
fold increase 48 hours after RIF treatment, which returned to normal in the next time point.  
For HNF1α-AS1, RIF treatment also did not induce its expression right after 24 hours. 
However, the expression of HNF1α-AS1 was induced for 2-fold at 48 hours after treatment and 
this induction remained in the later time points (Figure 4.2B).  
These results indicated that RIF treatment was able to induce the expression of HNF1α-AS1 
but has limited effects on the expression of HNF1α. 
 
4.3.3 Correlation between HNF1α-AS1 and CYP3A4 in RIF treated HepaRG cells 
To study the relationship between the expression of HNF1α-AS1 and CYP3A4 after RIF 
treatment, the correlation coefficient was calculated. A correlation coefficient of +0.85 was 
calculated between the relative expression of HNF1α-AS1 and CYP3A4, indicating the existence 







Figure 4. 2. Expression of HNF1α and HNF1α-AS1 after RIF treatment 
(A) Alteration in expression of HNF1α by RIF treatment in HepaRG cells. (B) Alteration in 
expression of HNF1α-AS1 by RIF treatment in HepaRG cells.  The sample size for each group is 
n = 3. Data are shown as mean ± SD. *p < 0.05 and **p < 0.01 versus control in two-tailed unpaired 






Drug mediated P450 induction is a common cause for DDI in clinical practice. Even this 
phenomenon has been reported for over four decades, the underlying molecular mechanism is still 
not fully explained yet. The identification of “xenobiotic sensor” transcription factors made a great 
progress in understanding the mechanisms in P450 induction. PXR, as one of the “xenobiotic 
sensor”, has been identified to induce the expression of CYP3A4 when stimulated by RIF [281].  
Knockdown of PXR in HepaRG cells resulted in abolished induction after RIF treatment, 
indicating that PXR is the major mediator in the induction of CYP3A4 by RIF treatment [282]. 
PXR was reported to mediate the transcription activation by binding to the response elements in 
the promoter region of CYP3A4. However, what molecular changes happen after PXR binding is 
still under investigation. 
In recent studies, several cofactors, including other transcription factors and epigenetic 
modifying enzymes, have been identified to play critical roles after PXR binding to CYP3A4 and 
mediate the transcription activation of CYP3A4 [23,279]. These studies suggest the existence of a 
complex regulatory mechanism between the processes of PXR binding and CYP3A4 induction. 
In the current study, we studied how RIF treatment altered gene expression in HepaRG cells 
at different time points. The induction of CYP3A4 was observed at all tested time points with 
different levels of induction. The highest induction level was found at 48 hours after RIF treatment 
and the induction of CYP3A4 persisted 120 hours after RIF treatment. The levels of CYP3A4 
started to drop after 48 hours, indicating that the induction was a relatively reversible process. One 
study reported that the treatment of pregnenolone 16α-carbonitrile, a mouse PXR activator, in the 
early age of mice led to persistently induction ofCYP3A11 through alteration of histone 
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modifications in the PXR response elements of the Cyp3a11 promoter [283], indicating that PXR 
activation might lead to permanent regulation to its target genes. However, how the histone 
memory of CYP3A4 changed and whether the expression of CYP3A4 will resume to a normal 
level is not known in RIF treated HepaRG cells. Future studies with a longer observation time and 
experiments investigating the histone signature of CYP3A4 would be recommended to answer 
these questions. 
LncRNAs have been recently found to involve in almost every step of gene regulation. In our 
previous studies, we identified that lncRNA HNF1α-AS1, a neighborhood lncRNA to transcription 
factor HNF1α, was able to regulate the expression of several P450s and transcription factors. 
However, whether lncRNAs also involved in the induction of CYP3A4 upon PXR activation by 
RIF has not been studied yet. In the current study, we observed that expression of HNF1α-AS1 
was also induced by RIF treatment. Interestingly, the coding gene HNF1α also showed a mild 
induction 48 hours after RIF treatment, at which point the HNF1α-AS1 also showed the highest 
expression. HNF1α-AS1 has been reported to be regulated by HNF1α [284]. In this case, the 
upregulation of HNF1α-AS1 might have resulted from HNF1α induction. The expression of PXR 
was also found to be upregulated after RIF treatment. Whether this upregulation of PXR is 
mediated by HNF1α-AS1 is not known. Further, a positive correlation between HNF1α-AS1 and 
CYP3A4 was observed, which also indicated that HNF1α-AS1 might involve in the induction of 
CYP3A4. However, to really investigate whether lncRNA HNF1α-AS1 is a critical factor in the 
PXR mediated induction of CYP3A4, a loss-of-function model is still needed. 
In summary, in the current part of the study, we found that RIF was able to induce the 
expression of CYP3A4, HNF1α-AS1, HNF1α, and PXR. However, how these factors work 
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together is still not clear and future studies using HNF1α-AS1 knockdown model are needed to 




Chapter 5. Summary and Future Directions 
 
The studies discussed in this dissertation fill in a knowledge gap by identifying lncRNAs 
involved in xenobiotic metabolism by regulating hepatic P450s. In the current study, two 
transcription factor neighborhood lncRNAs, HNF1α-AS1 and HNF4α-AS1, were functionally 
characterized. In order to study the functions of HNF1α-AS1 and HNF4α-AS1, lncRNA loss-of-
function models were generated using siRNA and shRNA transfection into HepaRG cells. In the 
first set of experiments (Chapter 2), we found the expression of P450s in HepaRG cells was 
regulated by a network composed of transcription factors and lncRNAs. Knockdown of HNF1α-
AS1 or HNF4α-AS1 affected the expression of several P450s and P450 regulatory transcription 
factors, including PXR and CAR, in HepaRG cells. The effects of lncRNA knockdown to P450 
expression were found to be opposite between HNF1α-AS1 and HNF4α-AS1 knockdown. 
Knockdown of HNF1α-AS1 led to P450 repression, while knockdown of HNF4α-AS1 resulted in 
upregulation of P450s. Furthermore, the expression of HNF1α-AS1 and HNF4α-AS1 was depleted 
by knocking down of their neighborhood coding gene encoded proteins, HNF1α and HNF4α, 
respectively, indicating that the lncRNAs were regulated by their neighborhood coding gene 
encoded proteins. The major finding of Chapter 2 is that lncRNAs are involved in transcription 
regulation of P450s in HepaRG cells. 
In the next part of the study (Chapter 3), we further investigated whether knockdown of 
HNF1α-AS1 or HNF4α-AS1 also affected P450 mediated drug biotransformation and drug 
toxicity. Using APAP as a model drug, we found that HNF1α-AS1 or HNF4α-AS1 knockdown 
changed the susceptibility of HepaRG cells to APAP, also in the opposite way. As showed by 
several toxicity and cell viability assays, HNF1α-AS1 knockdown decreased APAP induced 
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cytotoxicity, while HNF4α-AS1 knockdown exacerbated APAP induced cytotoxicity. The 
analysis of excretion alteration to Phase I and II enzymes involved in APAP biotransformation 
showed that P450 alteration, in both mRNA and protein levels, by lncRNA knockdown is the 
major cause of differential responses to APAP. The conclusion for this study is that lncRNAs were 
able to affect drug metabolism process and drug toxicity by affecting P450 expression and function. 
In Chapter 4, HNF1α-AS1 was found to respond to RIF treatment in HepaRG cells, indicating 
that lncRNAs might also involve in P450 induction by drug treatment. 
The current studies are just a good start in understanding lncRNAs in the field of drug 
metabolism. Many questions still exist and remain to be addressed in future studies: 1) Which is 
the primary target of HNF1α-AS1 and HNF4α-AS1, P450 genes, or transcription factors; 2) Are 
the functions of HNF1α-AS1 and HNF4α-AS1 depend on HNF1α and HNF4α or the two lncRNAs 
can function independently of their neighborhood coding genes; 3) Whether HNF1α-AS1 and 
HNF4α-AS1 affect characteristics of P450 genes and related transcription factor, such as 
epigenetic markers.  
Before answering these questions, one fundamental question needs to be addressed: what are 
interacting molecules to HNF1α-AS1 and HNF4α-AS1. According to previous research, HNF1α-
AS1 has been reported to interact with both miRNAs and proteins to regulate cellular functions in 
several cancer cells. In this case, it is rational to hypothesize that HNF1α-AS1 and HNF4α-AS1 
also perform their P450 regulatory functions by interacting with miRNAs and proteins. 
Several miRNAs were predicted to interact with HNF1α-AS1 and HNF4α-AS1 using ENCORI 
program, an online database focusing on miRNA-target interactions. Among these miRNAs, some 
were reported to involve in P450 expression [285]. Validation of these predicted miRNA-lncRNA 
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interactions would be a good start to study whether miRNA sponge is one mechanism in P450 
regulation by HNF1α-AS1 and HNF4α-AS1. To analyze lncRNA-Protein interactions, RNA-
Protein pull-down assays and RNA immunoprecipitation (RIP) are widely used [286]. 
Identification and characterization of the HNF1α-AS1 and HNF4α-AS1 interacting proteins will 
give hints about whether HNF1α-AS1 and HNF4α-AS1 can function as protein decoys or scaffolds.  
A better model is also needed in the future studies. While the current described studies are 
performed in cell based in vitro models, an in vivo model will be much better in mimicking human 
conditions. In the mouse genome, mouse Hnf1α and Hnf4α genes are also companioned by two 
lncRNA genes, named Hnf1αos1 and Hnf4αos1. Based on the results of sequence alignment, 
mouse Hnf1αos1 and Hnf4αos1 can be considered as homolog lncRNAs to human HNF1α-AS1 
and HNF4α-AS1. However, very limited studies have been done regarding these two mouse 
lncRNAs. We have tried to knockdown Hnf1αos1 by injection adeno-associated virus containing 
shRNAs targeting Hnf1αos1. However, the knockdown efficiency is very limited. Other gene-
editing methods, such as CRISPR-Cas9 system, could serve as an alternative way to knockdown 
these lncRNAs in mouse liver. Another model is the humanized liver mouse model, which was 
reported to have human-like metabolic responses to drugs [287].  
The goal of the current research is to understand how HNF1α-AS1 and HNF4α-AS1 affect the 
metabolic function in humans. The generated knowledge could help to improve drug efficacy and 
safety in clinical usages. However, several barriers still exist to achieve this.  
First, to what extent can these two lncRNAs affect liver function in humans or drug metabolism 
in clinical drug uses remains to be determined. In the current study, most of the results were 
generated using a loss-of-function in vitro model. However, this model has limitations in 
representing the actual expression variations of HNF1α-AS1 or HNF4α-AS1 in the population, as 
135 
 
well as the actual effects of lncRNA to P450 function. Second, the significances of lncRNAs are 
still ignored in clinical practice. Comparing to variations or mutations to coding genes, the patients’ 
noncoding gene signatures are generally not tested or recorded. Variations of lncRNAs are also 
not taken into consideration when giving prescriptions or generating treatment strategies.  
To overcome these barriers, several future studies need to be performed. In the first place, how 
the levels of HNF1α-AS1 or HNF4α-AS1 are distributed in the population should be measured. 
Getting to know the extent of interindividual variances of HNF1α-AS1 and HNF4α-AS1 is critical 
to predict whether these two lncRNAs have significant impacts on hepatic function. In the 
following step, studies should be performed to collect data regarding the correlations between 
HNF1α-AS1/ HNF4α-AS1 levels in humans and their hepatic functions, activities of specific P450 
isoforms, and drug responses. With an increasing number of studies showing the importance of 
lncRNA to human health, more attention should be put on how lncRNAs affect clinical outcomes 
in drug efficacy and toxicity.  
Finally, HNF1α-AS1 and HNF4α-AS1 are potential drug targets for future drug designs. 
HNF1α-AS1 and HNF4α-AS1 have been found to highly involved in physiological and 
pathological activities in humans, making them great potential targets to treat diseases [288,289]. 
Conventional drugs and the recently developed siRNA-based drugs targeting HNF1α-AS1 and 
HNF4α-AS1, or other lncRNAs with potential therapeutic benefits might be novel treatment 
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